BAB 5
SIMPULAN

5.1. Simpulan

Konsentrasi Ac-Di-Sol berpengaruh secara signifikan terhadap peningkatan kerapuhan tablet, mempercepat waktu hancur tablet, dan meningkatkan rasio absorpsi air ODT domperidone, namun tidak berpengaruh signifikan terhadap kekerasan tablet, waktu pembasahan, dan %ED. Konsentrasi gelatin berpengaruh signifikan terhadap peningkatan waktu hancur tablet dan waktu pembasahan ODT domperidone, namun tidak berpengaruh signifikan terhadap kekerasan tablet, kerapuhan tablet, rasio absorpsi air, dan %ED. Interaksi konsentrasi Ac-Di-Sol dan konsentrasi gelatin tidak berpengaruh secara signifikan terhadap sifat fisik dan profil pelepasan ODT domperidone secara *in vitro*.

Formula optimum ODT domperidone dapat diperoleh dengan kombinasi *superdisintegrant* Ac-Di-Sol dengan konsentrasi 2,78% dan konsentrasi gelatin 1,07%, yang akan memberikan prediksi hasil respon kekerasan tablet 2,90 Kp, kerapuhan tablet 0,70%, waktu hancur tablet 49,39 detik, waktu pembasahan 51,13 detik, rasio absorpsi air 58,38%, dan %ED 93,04%.

5.2. Alur Penelitian Selanjutnya

Perlu dilakukan uji stabilitas dengan waktu pengamatan yang lebih panjang, yaitu tidak kurang dari 3 bulan dan dilakukan penelitian pembuktian beberapa formula optimum terpilih, yang kemudian dibandingkan dengan hasil secara teoritis.

DAFTAR PUSTAKA

Agoes, G., 2006, Pengembangan Sediaan Farmasi, Institut Teknologi Bandung, Bandung, 187-190, 192.

Albright, L. M., 2004, Domperidone in Lactation: Use as a Galactagogue, **International Journal of Pharmaceutical Compounding**, 8 (5): 329-335.

Anderson, P.O., James, E.K., William, G.T., 2002, **Handbook of Clinical Drug Data**, 10th ed., Mc Graw Hill Companies, USA.

Anonim, 1979, **Farmakope Indonesia**, ed. III, Departemen Kesehatan RI, Jakarta, 6-8.

Anonim, 1995, **Farmakope Indonesia**, ed. IV, Departemen Kesehatan RI, Jakarta, 4, 166, 449-450, 488-489, 515, 683, 783-784, 999-1000.

Anonim, 2005, **European pharmacopeia**, 5th ed., EDQM, English, 1473-1475.

Anonim, 2006, **USP29-NF24**, General Information Chapter '<1174> Powder Flow', US Pharmacopeial Convention, Rockville, MD, USA.

Anonim, 2007, **US Pharmacopeia XXX**, US Pharmacopeial Convention Inc., Rockville.

Ansel, C.H., 1989, **Pengantar Bentuk Sediaan Farmasi**, ed. 4, Penerbit Universitas Indonesia, Jakarta, 244-245, 259-272.

Armstrong, N.A. and K.C. James, 1996, **Pharmaceutical Experimental Design and Interpretation: Factorial Design of Experiment**, Taylor and Francis, USA, 131-136.

Banakar, U.V., 1992, **Pharmaceutical Disolution Testing**, Marcel Dekker Inc., New York, 19-25.

Banker, G.S. and N.R. Anderson, 1986, Tablet, in: **The Theory and Practice of Industrial Pharmacy: Tablet**, L. Lachman, H.A. Lieberman, and J.L. Kanig (Eds.), 3rd ed., Lea and Febiger, Philadelphia, 259, 295, 299, 316 – 329.

Bhowmik, D. *et al*, 2009, Fast Dissolving Tablet: An Overview, **Journal of Chemical and Pharmaceutical Research**, 1(1): 163-177.

Bolton, S., 1997, **Pharmaceutical Statistic Practical and Clinical Application**, 3rd ed, Macel Dekker Inc., New York, 308-337, 532-574.

Brogden, R.N., Carmine, A.A., Heel, R.C., Speight, T.M., Avery, G.S., 1982, Domperidone: A Review of its Pharmacological Activity, Pharmacokinetics and Therapeutic Efficacy in the Symptomatic Treatment of Chronic Dyspepsia and as an Antiemetic, **Drugs**, 25(5): 353-452.

Camarco, W., D. Ray, and A. Druffner, 2006, Selecting Superdisintegrants for Orally Disintegrating Tablet Formulations, **Pharmaceutical Technology Supplement** s28-s37.

Deshmukh, V.N., 2012, Mouth Dissolving Drug Delivery System: A Review, **International Journal of PharmTech Research**, 4(1): 412-421.

Dibbern, H.W., R.M. Müller, E. Wirbitzki (Eds), 2002, **UV and IR Spectra**, Editio Cantor Verlag, German.

Dobetti L., 2003, Fast Disintegrating Tablets, **US Patent** 6, 596, 311.

Duchene, D., 1983, Tablet Disintegration, In: **Topic in Pharmaceutical Science**, P.D. Breimer, and P. Spesier (Eds.), Proceeding of The 43rd International Congreess of Pharmaceutical, Amsterdam – New York – Oxford, 387 – 399.

Forner, D.E., N.R. Anderson, G.S. Banker, T.W. Rosanske, and R.E. Gordon, 1981, Granulation and Tablet Characteristic. In: **Pharmaceutical Dosage Form**, Lieberman H.A., Lachman L., and J.B. Schwartz, (Eds.), Volume 2, Marcel Dekker,Inc., New York, 109 – 143, 188 – 190.

Fu, Y.R., Yang, S.C., Seong, H.J., Kimura, S. dan K. Park, 2004, Orally Fast Disintegrating Tablets: Developments, Technologies, Taste-Masking and Clinical Studies, **Critical Reviews in Therapeutic Drug Carrier Systems**, 21(6): 433–475.

Fudholi, A., 1985, Metodologi Formulasi dalam Kompresi Direk, **Medika**, 9: 586-593.

Giri, T.K., D.K. Tripathi, and R. Majumdar, 2010, Formulation Aspects In The Development of Orodispersible Tablets: An Overview, **International Journal of Pharmacy and Pharmaceutical Sciences**, 2(3): 38-42.

Goel, H., N. Vora, A.K. Tiwary, V. Rana, 2009, Formulation of Orodispersible Tablets of Ondansentron HCl: Investigation Using Glycine-Chitosan Mixture as Superdisintegrant, **Yakugaku Zasshi**, 129(5): 513-521.

Goel, H., P. Rai, V. Rana, A.K. Tiwary, 2008, Orally Disintegrating Systems: Innovations in Formulation and Technology, **Recent Patents on Drug Delivery & Formulation,** 2: 258-274.

Gohel, M.C. and P.D. Jogani, 2005, A Review Of Co-Processed Directly Compressible Excipients, **J. Pharm. Pharmaceut. Sci.**, 8(1):76-93.

Guleria, R., N.S. Kaith, R. Singh, 2011, Improved Dissolution of Domperidone In Solid Dispersion with Polymeric Hydrophillic Additive, **J. Chem. Pharm. Res.**, 3(6):655-664.

Hsu, A.F. and C-H Han, 2005, Oral Disintegrating Dosage Form, **US Patent Application Publication Number 20050147670A1**.

Kanani, R. and S. Rajarajan, 2011, Development and Characterization of Antibiotic Orodispersible Tablets, **International Journal of Current Pharmaceutical Research**, 3(3), 27-32.

Khan, K.A., 1975, The Concept of Dissolution Efficiency. **J. Pharm**, 27(1), 48-49.

Kumar, M.V., P. Sethi, R. Kheri, G. K. Saraogi, A. K. Singhai, 2011, Orally Disintegrating Tablets: A Review, **International Research Journal of Pharmacy**, 2(4), 16-22.

Lachman, L., H.A. Leiberman, and J.L. Kanig, 1986, **The Theory and Practice of Industrial Pharmacy**. 3rd Edition. Lea and Febiger, Philadelphia, 564 – 588.

Langenbucher, F., 1972, Linearization of Dissolution Rate Curve by Weibull Distribution, **Journal of Pharmaceutical Sciences**, 24, 979-981.

Lucas, T.I., R.H. Bishara, R.H. Seevers, 2004, A Stability Program for the Distribution of Drug Products, **Pharmaceutical Technology**, 7: 68-73.

Manivannan, R., 2009, Oral Disintegrating Tablets: A Future Compaction, **International Journal of Pharmaceutical Research and Development**, 1(10): 1-10.

Martin, A., J. Swarbrick, dan A. Cammarata, 1993, **Farmasi Fisik: Dasar-dasar Kimia Fisika dalam Ilmu Farmasetik**, vol. 2, ed. 3, terjemahan Yoshita, Universitas Indonesia, Jakarta, 1135.

Neal, M.J., 2002, **Medical Pharmacology at a Glance**, 4thed., Blackwell Science, British, 67.

Olayemi, O. and O. Jacob, 2011, Preliminary Evaluation of Brachystegia eurycoma Seed Mucilage as Tablet Binder, **International Journal of Pharmaceutical Research and Innovation**, 3: 1-6.

Parashar, B. and A. Chauhan, 2012, Formulation And Evaluation of Fast Disintegrating Tablets of Domperidone, **International Journal of Institutional Pharmacy and Life Sciences**, 2(3): 232-238.

Parmar, R.B. *et al.* , 2009, Formulation and Evaluation of Domperidone Fast Dissolving Tablets, **International Journal of PharmTech Research**, 1(3): 483-487.

Parrot, E.L., 1971, **Pharmaceutical Technology Fundamental Pharmaceutics**, 3rd ed., Burgess Publishing Company, Minneapolis, 17-19, 82, 160-162.

Patel, U., K. Patel, D. Shah, R. Shah, 2012, A Review On Immediate Release Drug Delivery System, **International Journal of Pharmaceutical Research and Bio-Science**, 1(5): 37-66.

Prajapati, B.G. and D.V. Patel, 2010, Comparative Study of Efficiency of Different Superdisintegrant for Fast Dissolve Tablet of Domperidone, **Journal of Pharmacy Research**, 3(1): 151-155.

Rowe, R.C., P. J. Sheskey, M.E. Qiunn, 2009, **Handbook of Pharmaceutical Excipients**, 6th ed., The Pharmaceutical Press, London, 164-169, 206-207, 278-281, 424-428, 517-522.

Shargel, L. and A.B.C. Yu, 1999, **Applied Biopharmaceutics and Pharmacokinetics,** 4th ed McGraw-Hill. New York, 8, 132, 169-200.

Sharma, S and P.K. Suresh, 2010, Formulation, In Vitro Characterization and Stability Studies of Self Microemulsifying Drug Delivery Systems of Domperidone, **International Journal of Innovative Pharmaceutical Research**, 1(4),66-73.

Sheth, B. B., Bandelin, F. J., Shangraw, R. F., 1980, **Compresed Tablets in Pharmaceuticals Dosage Farms: Tablets**, Vol. I, Lachman, L., Lieberman, H. A., (editor), Marcel Decker inc., New York.

Shihora, H. and S. Panda, 2011, Superdisintegrants, Utility in Dosage Forms: A Quick Review, **Journal of Pharmaceutical Science and Bioscientific Research**, 1(3): 148-153.

Shukla, D., Chakraborty, S., Singh, S. dan B. Mishra, 2009, Mouth Dissolving Tablets I: An Overview of For mulation Technology, **Scientia Pharmaceutica**, 76: 309-326.

Siregar, C.J.P., 1992, Proses Validasi dan Manufaktur Sediaan Tablet, dalam: Asyarie, S., U. Mar'u, dan S. Badruzzaman (Eds.), **Prosiding Seminar Validasi di Industri Farmasi. Jurusan Farmasi FMIPA ITB**, Bandung, 26 – 41.

Soedigdo, S. and P. Soedigdo, 1977, **Pengantar Cara Statistika Kimia**, Institut Teknologi Bandung, Bandung, 29-31.

Sweetman, S.C., 2009, **Martindale: The Complete Drug Reference**, 36th ed., Pharmaceutical Pres., London, 1726.

Thatipamula, R.P., C.R. Palem, R. Gannu, S. Mudragada, M. R. Yamsani, 2011, Fomulation and In Vitro Characterization of Domperidone Loaded Solid Lipid Nanoparticles and Nanostructured Lipid Carriers, **DARU**, 19(1): 23-32.

Wagner, J.G., 1971, **Biopharmaceutics and Relevant Pharmacokinetics**, 1st ed., Drug Intelligence Publications, Illinois, 64-110.

Ward, B.A., Alan, M., Abdullah, K., Raymond, E.G., Davis, A.F., Zeruesenay, D., 2004, Characterization of Human Cytochrome P450

Enzymes Catalyzing Domperidone N-Dealkylation and Hydroxylation in Vitro, **Br. J. Clin. Pharmacol.**, 58(3): 277-287.

Yadav, V., Bharat P., Brajesh M., Love S., 2012, Fast Dissolving Tablet, **International Journal of Apllied Pharmaceutics**, Vol 4 (2), 17-22.

Zainuddin, M., 2000, **Validasi Metode Analisis Kuantitatif Secara Spektrofotometris Ultra Ungu-Sinar Tampak (UV-Vis)**, Universitas Airlangga, Surabaya.

LAMPIRAN A

HASIL UJI MUTU FISIK GRANUL

Mutu fisik yang diuji	Rep.	Uji	Formula ODT Domperidone				Persyaratan
			F1	F2	F3	F4	
Kelembapan (%)	I	-	2,57	3,24	2,68	3,44	2-5% (Ansel, 1989)
	II	-	3,04	3,29	3,08	3,35	
	III	-	2,98	3,09	3,15	3,13	
	X□		2,86	3,21	2,97	3,31	
	SD		0,26	0,10	0,25	0,16	
Densitas (g/mL)	I	ρ bulk	0,4620	0,4894	0,4454	0,4726	-
		ρ tapped	0,5435	0,6117	0,5303	0,5695	
	II	ρ bulk	0,4371	0,4781	0,5214	0,4535	
		ρ tapped	0,5024	0,5761	0,6062	0,5399	
	III	ρ bulk	0,4623	0,4510	0,4963	0,4492	
		ρ tapped	0,5439	0,5637	0,5908	0,5348	
	X□	ρ bulk	0,4538	0,4728	0,4877	0,4585	
	SD	ρ bulk	0,014	0,020	0,039	0,012	
	X□	ρ tapped	0,5299	0,5838	0,5758	0,5481	
	SD	ρ tapped	0,024	0,025	0,040	0,019	
Hausner Ratio	I	-	1,18	1,25	1,19	1,20	≤ 1,25 (Anonim, 2006)
	II	-	1,15	1,20	1,16	1,19	
	III	-	1,18	1,25	1,19	1,19	
	X□		1,17	1,23	1,18	1,20	
	SD		0,02	0,03	0,02	0,01	
Carr's Index (%)	I	-	15	20	16	17	≤ 20 (Anonim, 2006)
	II	-	13	17	14	16	
	III	-	15	20	16	16	
	X□		14,33	19,00	15,33	16,33	
	SD		1,15	1,73	1,15	0,58	

LAMPIRAN B

HASIL UJI KERAGAMAN BOBOT ODT DOMPERIDONE

Formula I

No	Replikasi I		Replikasi II		Replikasi III	
	Bobot Tablet (mg)	Y (%)	Bobot Tablet (mg)	Y (%)	Bobot Tablet (mg)	Y (%)
1	95,5	97,78	108,7	108,70	103,0	103,17
2	96,7	99,00	108,1	108,10	105,0	105,17
3	98,2	100,54	106,4	106,40	105,2	105,37
4	98,2	100,54	105,9	105,90	93,7	93,85
5	98,9	101,26	106,2	106,20	104,6	104,77
6	99,8	102,18	108,3	108,30	103,3	103,47
7	96,1	98,39	105,3	105,30	102,7	102,87
8	94,8	97,06	106,3	106,30	104,1	104,27
9	94,2	96,44	107,4	107,40	101,9	102,07
10	95,6	97,88	108,4	108,40	96,8	96,96
X□	96,80	99,11	107,10	107,10	102,03	102,20
PK (%)	99,11		107,10		102,20	
SD	1,92		1,22		3,80	
KV	1,94		1,14		3,72	

Formula II

No	Replikasi I		Replikasi II		Replikasi III	
	Bobot Tablet (mg)	Y (%)	Bobot Tablet (mg)	Y (%)	Bobot Tablet (mg)	Y (%)
1	102,9	101,18	107,5	103,41	103,8	102,28
2	102,3	100,59	108,3	104,18	103,7	102,18
3	104,5	102,76	107,9	103,79	101,7	100,21
4	105,8	104,04	110,1	105,91	103,2	101,69
5	104,1	102,36	110,2	106,00	102,1	100,60
6	103,6	101,87	109,9	105,72	102,6	101,09
7	105,1	103,35	108,7	104,56	104,1	102,57
8	104,7	102,95	111,7	107,45	101,9	100,40
9	105,7	103,94	109,6	105,43	103,8	102,28
10	103,2	101,48	109,4	105,24	104,1	102,57
X□	104,19	102,45	109,33	105,17	103,10	101,59
PK (%)	102,45		105,17		101,59	
SD	1,16		1,21		1,16	
KV	1,14		1,15		1,14	

Formula III

No	Replikasi I		Replikasi II		Replikasi III	
	Bobot Tablet (mg)	Y (%)	Bobot Tablet (mg)	Y (%)	Bobot Tablet (mg)	Y (%)
1	103,3	105,64	111,1	109,27	109,7	107,19
2	101,6	103,91	108,7	106,91	107,2	104,75
3	101,3	103,60	109,5	107,70	103,7	101,33
4	101,4	103,70	105,7	103,96	108,8	106,31
5	102,6	104,93	105,3	103,57	101,2	98,89
6	102,4	104,72	109,3	107,50	102,3	99,96
7	103,2	105,54	107,7	105,93	103,2	100,84
8	101,7	104,01	108,6	106,81	106,8	104,36
9	102,1	104,42	107,9	106,12	105,9	103,48
10	103,0	105,34	108,2	106,42	106,9	104,46
X□	102,26	104,58	108,20	106,42	105,57	103,16
PK (%)	104,58		106,42		103,16	
SD	0,77		1,69		2,77	
KV	0,73		1,59		2,69	

Formula IV

No	Replikasi I		Replikasi II		Replikasi III	
	Bobot Tablet (mg)	Y (%)	Bobot Tablet (mg)	Y (%)	Bobot Tablet (mg)	Y (%)
1	109,6	113,33	104,9	103,86	105,9	104,55
2	101,7	105,16	101,5	100,49	101,7	100,40
3	101,5	104,95	100,0	99,00	102,2	100,90
4	101,9	105,37	97,0	96,03	103,0	101,69
5	102,9	106,40	102,0	100,98	102,9	101,59
6	102,4	105,88	105,2	104,15	102,4	101,09
7	103,2	106,71	103,1	102,07	104,1	102,77
8	101,7	105,16	104,7	103,66	100,8	99,52
9	102,1	105,57	104,8	103,76	102,1	100,80
10	103,0	106,50	102,3	101,28	103,3	101,98
X□	103,00	106,50	102,55	101,53	102,84	101,53
PK (%)	106,50		101,53		101,53	
SD	2,48		2,58		1,39	
KV	2,33		2,55		1,37	

LAMPIRAN C

HASIL UJI KESERAGAMAN KANDUNGAN ODT DOMPERIDONE

Formula I

Rep.	Abs.	Bobot Tablet (mg)	Bobot Sampel (mg)	Kons. Sampel (µg/ml)	Kons. Teoritis (µg/ml)	Kadar (%)
	0,241	95,5	90,3	7,43	7,56	98,19
	0,249	96,7	90,8	7,71	7,51	102,64
	0,242	98,2	93,3	7,46	7,60	98,19
	0,241	98,2	91,0	7,43	7,41	100,19
	0,242	98,9	92,1	7,46	7,45	100,18
	0,249	99,8	93,4	7,71	7,49	102,98
I	0,245	96,1	91,0	7,57	7,58	99,91
	0,243	94,8	90,2	7,50	7,61	98,51
	0,239	94,2	89,4	7,36	7,59	96,90
	0,245	95,6	90,1	7,57	7,54	100,39
					X□	99,81
					SD	1,95
					KV	1,95
	0,261	108,7	103,4	8,13	7,61	106,88
	0,262	108,1	102,7	8,17	7,60	107,48
	0,263	106,4	101,3	8,20	7,62	107,72
	0,254	105,9	100,3	7,89	7,58	104,09
	0,259	106,2	101,7	8,06	7,66	105,25
	0,254	108,3	102,8	7,89	7,59	103,86
II	0,242	105,3	99,8	7,46	7,58	98,43
	0,261	106,3	101,2	8,13	7,62	106,80
	0,258	107,4	102,1	8,03	7,61	105,56
	0,245	108,4	101,6	7,57	7,50	100,94
					X□	104,70
					SD	3,01
					KV	2,87

Rep.	Abs.	Bobot Tablet (mg)	Bobot Sampel (mg)	Kons. Sampel (µg/ml)	Kons. Teoritis (µg/ml)	Kadar (%)
	0,253	103,0	97,7	7,85	7,59	103,47
	0,239	105,0	99,2	7,36	7,56	97,34
	0,248	105,2	99,4	7,67	7,56	101,53
	0,246	93,7	88,7	7,60	7,57	100,41
	0,251	104,6	99,9	7,78	7,64	101,84
	0,249	103,3	96,2	7,71	7,45	103,49
III	0,248	102,7	96,8	7,67	7,54	101,78
	0,259	104,1	99,3	8,06	7,63	105,66
	0,252	101,9	95,8	7,82	7,52	103,92
	0,249	96,8	91,6	7,71	7,57	101,85
					X□	102,13
					SD	2,26
					KV	2,21

Formula II

Rep.	Abs.	Bobot Tablet (mg)	Bobot Sampel (mg)	Kons. Sampel (µg/ml)	Kons. Teoritis (µg/ml)	Kadar (%)
	0,258	102,9	97,8	8,03	7,60	105,58
	0,255	102,3	97,4	7,92	7,62	104,01
	0,251	104,5	98,9	7,78	7,57	102,77
	0,249	105,8	99,8	7,71	7,55	102,17
	0,249	104,1	99,5	7,71	7,65	100,83
	0,246	103,6	98,1	7,60	7,58	100,38
I	0,245	105,1	94,6	7,57	7,20	105,11
	0,247	104,7	99,5	7,64	7,60	100,49
	0,248	105,7	99,5	7,67	7,53	101,91
	0,254	103,2	98,2	7,89	7,61	103,60
					X□	102,69
					SD	1,87
					KV	1,82
	0,247	107,5	102,3	7,64	7,61	100,35
	0,249	108,3	103,2	7,71	7,62	101,14
	0,250	107,9	102,5	7,75	7,60	101,92
	0,245	110,1	106,4	7,57	7,73	97,90
	0,247	110,2	105,7	7,64	7,67	99,56
	0,251	109,9	104,5	7,78	7,61	102,29
II	0,253	108,7	103,6	7,85	7,62	102,97
	0,249	111,7	106,1	7,71	7,60	101,46
	0,255	109,6	104,5	7,92	7,63	103,86
	0,251	109,4	104,1	7,78	7,61	102,21
					X□	101,37
					SD	1,73
					KV	1,71
	0,257	103,8	98,2	7,99	7,57	105,60
	0,254	103,7	99,3	7,89	7,66	102,95
	0,259	101,7	96,9	8,06	7,62	105,78
	0,257	103,2	100,4	7,99	7,78	102,69
	0,250	102,1	97,8	7,75	7,66	101,07
	0,258	102,6	97,9	8,03	7,63	105,17
III	0,254	104,1	99,4	7,89	7,64	103,24
	0,262	101,9	96,4	8,17	7,57	107,94
	0,253	103,8	98,9	7,85	7,62	103,00
	0,256	104,1	99,3	7,96	7,63	104,27
					X□	104,17
					SD	1,98
					KV	1,90

Formula III

Rep.	Abs.	Bobot Tablet (mg)	Bobot Sampel (mg)	Kons. Sampel (µg/ml)	Kons. Teoritis (µg/ml)	Kadar (%)
I	0,261	103,3	98,2	8,13	7,61	106,95
	0,259	101,6	96,9	8,06	7,63	105,68
	0,264	101,3	97,0	8,24	7,66	107,56
	0,261	101,4	97,2	8,13	7,67	106,06
	0,257	102,6	97,8	7,99	7,63	104,81
	0,248	102,4	97,6	7,67	7,63	100,65
	0,257	103,2	98,6	7,99	7,64	104,57
	0,256	101,7	96,6	7,96	7,60	104,72
	0,245	102,1	97,3	7,57	7,62	99,28
	0,257	103,0	98,4	7,99	7,64	104,58
					X□	104,49
					SD	2,61
					KV	2,50
II	0,254	111,1	107,3	7,89	7,73	102,07
	0,256	108,7	104,1	7,96	7,66	103,86
	0,253	109,5	104,6	7,85	7,64	102,74
	0,258	105,7	101,2	8,03	7,66	104,81
	0,260	105,3	101,8	8,10	7,73	104,71
	0,261	109,3	103,9	8,13	7,60	106,96
	0,259	107,7	102,0	8,06	7,58	106,42
	0,252	108,6	104,1	7,82	7,67	101,92
	0,261	107,9	103,8	8,13	7,70	105,69
	0,252	108,2	104,1	7,82	7,70	101,55
					X□	104,07
					SD	1,95
					KV	1,87
III	0,260	109,7	104,9	8,10	7,65	105,86
	0,267	107,2	102,4	8,35	7,64	109,21
	0,261	103,7	99,2	8,13	7,65	106,28
	0,258	108,8	103,9	8,03	7,64	105,08
	0,254	101,2	97,2	7,89	7,68	102,64
	0,258	102,3	97,4	8,03	7,62	105,40
	0,259	103,2	98,9	8,06	7,67	105,17
	0,259	106,8	102,9	8,06	7,71	104,61
	0,262	105,9	101,1	8,17	7,64	106,96
	0,268	106,9	102,4	8,38	7,66	109,36
					X□	106,06
					SD	2,05
					KV	1,93

Formula IV

Rep.	Abs.	Bobot Tablet (mg)	Bobot Sampel (mg)	Kons. Sampel (µg/ml)	Kons. Teoritis (µg/ml)	Kadar (%)
	0,251	109,6	104,9	7,78	7,66	101,62
	0,252	101,7	97,2	7,82	7,65	102,22
	0,250	101,5	97,0	7,75	7,65	101,31
	0,256	101,9	97,5	7,96	7,65	103,95
	0,245	102,9	93,1	7,57	7,24	104,57
	0,245	102,4	97,7	7,57	7,63	99,16
I	0,241	103,2	98,4	7,43	7,63	97,38
	0,251	101,7	97,0	7,78	7,63	101,97
	0,255	102,1	97,5	7,92	7,64	103,70
	0,248	103,0	98,1	7,67	7,62	100,73
					X□	101,66
					SD	2,21
					KV	2,17
	0,254	104,9	99,7	7,89	7,60	103,72
	0,253	101,5	96,5	7,85	7,61	103,23
	0,256	100,0	96,1	7,96	7,69	103,50
	0,259	97,0	92,3	8,06	7,61	105,92
	0,261	102,0	98,5	8,13	7,73	105,28
	0,259	105,2	100,5	8,06	7,64	105,50
II	0,266	103,1	98,3	8,31	7,63	108,95
	0,260	104,7	98,9	8,10	7,56	107,17
	0,256	104,8	99,9	7,96	7,63	104,34
	0,269	102,3	97,7	8,42	7,64	110,15
					X□	105,78
					SD	2,34
					KV	2,22
	0,245	105,9	101,2	7,57	7,64	99,01
	0,237	101,7	97,1	7,29	7,64	95,40
	0,238	102,2	97,8	7,32	7,66	95,64
	0,239	103,0	98,2	7,36	7,63	96,46
	0,236	102,9	98,5	7,25	7,66	94,69
	0,245	102,4	97,9	7,57	7,65	98,96
III	0,250	104,1	100,1	7,75	7,69	100,69
	0,241	100,8	96,1	7,43	7,63	97,39
	0,249	102,1	97,7	7,71	7,66	100,72
	0,242	103,3	98,8	7,46	7,65	97,54
					X□	97,65
					SD	2,15
					KV	2,20

LAMPIRAN D

HASIL UJI KESERAGAMAN UKURAN ODT DOMPERIDONE

Formula I

No.	Replikasi I		Replikasi II		Replikasi III	
	Diameter Tablet (cm)	Tebal Tablet (cm)	Diameter Tablet (cm)	Tebal Tablet (cm)	Diameter Tablet (cm)	Tebal Tablet (cm)
1	0,610	0,320	0,615	0,355	0,610	0,360
2	0,605	0,320	0,610	0,345	0,620	0,360
3	0,610	0,330	0,610	0,360	0,610	0,360
4	0,605	0,310	0,610	0,350	0,610	0,355
5	0,610	0,320	0,610	0,360	0,610	0,360
6	0,610	0,315	0,605	0,365	0,610	0,360
7	0,610	0,320	0,610	0,370	0,610	0,360
8	0,610	0,330	0,610	0,370	0,615	0,365
9	0,610	0,330	0,610	0,375	0,615	0,360
10	0,610	0,330	0,610	0,370	0,610	0,360
11	0,610	0,325	0,610	0,350	0,610	0,355
12	0,615	0,325	0,610	0,350	0,610	0,350
13	0,615	0,330	0,620	0,355	0,610	0,350
14	0,610	0,320	0,610	0,370	0,610	0,360
15	0,610	0,325	0,610	0,370	0,620	0,365
16	0,610	0,330	0,610	0,365	0,610	0,350
17	0,610	0,330	0,610	0,360	0,610	0,360
18	0,615	0,335	0,615	0,360	0,610	0,355
19	0,610	0,325	0,610	0,355	0,610	0,350
20	0,610	0,335	0,610	0,360	0,605	0,340
X□	0,610	0,325	0,611	0,361	0,611	0,357
SD	0,00	0,01	0,00	0,01	0,00	0,01
KV	0,42	2,02	0,48	2,35	0,59	1,72

Formula II

No.	Replikasi I		Replikasi II		Replikasi III	
	Diameter Tablet (cm)	**Tebal Tablet (cm)**	**Diameter Tablet (cm)**	**Tebal Tablet (cm)**	**Diameter Tablet (cm)**	**Tebal Tablet (cm)**
1	0,610	0,340	0,610	0,350	0,610	0,350
2	0,610	0,350	0,610	0,350	0,610	0,360
3	0,610	0,345	0,610	0,370	0,610	0,355
4	0,610	0,350	0,605	0,360	0,610	0,340
5	0,610	0,360	0,610	0,350	0,610	0,350
6	0,610	0,360	0,605	0,360	0,610	0,345
7	0,610	0,340	0,610	0,350	0,610	0,365
8	0,615	0,360	0,610	0,340	0,615	0,355
9	0,610	0,365	0,610	0,350	0,610	0,360
10	0,605	0,360	0,610	0,345	0,610	0,350
11	0,610	0,360	0,610	0,340	0,610	0,370
12	0,605	0,355	0,610	0,355	0,605	0,370
13	0,610	0,360	0,610	0,360	0,610	0,350
14	0,610	0,365	0,615	0,350	0,615	0,340
15	0,610	0,350	0,610	0,350	0,610	0,345
16	0,610	0,345	0,610	0,350	0,605	0,350
17	0,610	0,360	0,610	0,370	0,610	0,350
18	0,610	0,360	0,610	0,350	0,605	0,355
19	0,610	0,340	0,610	0,360	0,610	0,360
20	0,615	0,360	0,610	0,370	0,610	0,370
X□	0,610	0,354	0,610	0,354	0,610	0,355
SD	0,00	0,01	0,00	0,01	0,00	0,01
KV	0,38	2,39	0,32	2,53	0,42	2,62

Formula III

No.	Replikasi I		Replikasi II		Replikasi III	
	Diameter Tablet (cm)	**Tebal Tablet (cm)**	**Diameter Tablet (cm)**	**Tebal Tablet (cm)**	**Diameter Tablet (cm)**	**Tebal Tablet (cm)**
1	0,610	0,350	0,605	0,350	0,620	0,360
2	0,610	0,450	0,610	0,340	0,610	0,355
3	0,610	0,330	0,610	0,350	0,615	0,360
4	0,610	0,330	0,610	0,340	0,610	0,365
5	0,610	0,330	0,610	0,340	0,610	0,370
6	0,610	0,340	0,610	0,350	0,620	0,355
7	0,615	0,330	0,610	0,340	0,615	0,360
8	0,610	0,355	0,610	0,350	0,610	0,370
9	0,610	0,330	0,610	0,340	0,610	0,375
10	0,610	0,340	0,620	0,350	0,610	0,360
11	0,615	0,330	0,615	0,360	0,605	0,370
12	0,610	0,330	0,610	0,345	0,610	0,365
13	0,610	0,350	0,610	0,340	0,620	0,355
14	0,605	0,350	0,615	0,340	0,610	0,370
15	0,610	0,330	0,610	0,365	0,610	0,360
16	0,610	0,330	0,610	0,360	0,610	0,360
17	0,610	0,345	0,605	0,370	0,615	0,365
18	0,620	0,330	0,610	0,360	0,605	0,370
19	0,610	0,340	0,610	0,350	0,610	0,360
20	0,610	0,350	0,610	0,340	0,615	0,350
X□	0,611	0,344	0,611	0,349	0,612	0,363
SD	0,00	0,03	0,00	0,01	0,00	0,01
KV	0,48	7,76	0,52	2,73	0,72	1,82

Formula IV

No.	Replikasi I		Replikasi II		Replikasi III	
	Diameter Tablet (cm)	**Tebal Tablet (cm)**	**Diameter Tablet (cm)**	**Tebal Tablet (cm)**	**Diameter Tablet (cm)**	**Tebal Tablet (cm)**
1	0,610	0,360	0,610	0,360	0,610	0,360
2	0,610	0,360	0,610	0,360	0,610	0,360
3	0,610	0,350	0,615	0,365	0,605	0,360
4	0,150	0,370	0,610	0,355	0,610	0,365
5	0,610	0,360	0,610	0,355	0,610	0,355
6	0,610	0,360	0,605	0,360	0,615	0,360
7	0,615	0,360	0,610	0,360	0,610	0,360
8	0,615	0,365	0,610	0,355	0,610	0,360
9	0,605	0,350	0,615	0,360	0,610	0,350
10	0,605	0,360	0,605	0,360	0,605	0,355
11	0,605	0,360	0,610	0,365	0,610	0,360
12	0,610	0,355	0,610	0,355	0,610	0,360
13	0,615	0,365	0,615	0,370	0,610	0,355
14	0,610	0,355	0,610	0,360	0,610	0,365
15	0,610	0,355	0,610	0,360	0,615	0,355
16	0,605	0,360	0,605	0,350	0,610	0,350
17	0,615	0,360	0,615	0,370	0,610	0,355
18	0,615	0,355	0,610	0,360	0,605	0,360
19	0,610	0,360	0,610	0,360	0,610	0,365
20	0,610	0,380	0,605	0,360	0,610	0,360
X□	0,587	0,360	0,610	0,360	0,610	0,359
SD	0,10	0,01	0,00	0,00	0,00	0,00
KV	17,54	1,86	0,53	1,35	0,42	1,21

LAMPIRAN E

HASIL UJI KEKERASAN ODT DOMPERIDONE

No.	Kekerasan ODT Domperidone (Kp)											
	Formula 1			Formula 2			Formula 3			Formula 4		
	I	II	III	I	II	III	I	II	III	I	II	III
1	3,2	2,9	2,9	2,8	2,8	2,2	4,7	3,6	3,0	2,8	2,6	2,9
2	2,8	3,1	2,6	2,6	3,4	2,7	3,6	2,8	3,1	3,2	2,2	3,1
3	2,4	3,4	2,7	3,0	2,2	2,5	2,5	3,6	3,0	3,4	3,1	3,3
4	2,6	2,6	2,5	2,5	2,6	3,5	2,6	3,8	3,4	3,0	2,2	3,7
5	2,9	3,3	2,7	3,3	2,9	3,3	2,7	3,5	2,8	2,6	2,3	2,6
6	2,3	3,4	2,6	2,6	2,8	2,7	3,0	3,1	3,4	3,3	2,2	2,2
7	3,1	3,1	2,6	2,4	3,0	2,8	3,1	3,3	3,3	2,6	2,6	3,1
8	3,1	3,3	2,6	2,8	2,4	2,7	2,8	3,8	3,1	2,4	3,0	3,2
9	3,7	2,1	2,9	3,2	2,8	2,6	3,1	3,2	3,7	2,8	2,5	3,6
10	2,8	3,5	3,1	3,3	2,3	2,9	3,1	3,0	3,0	2,9	2,6	3,9
X□	2,89	3,07	2,72	2,85	2,72	2,79	3,12	3,37	3,18	2,90	2,53	3,16
SD	0,41	0,43	0,19	0,33	0,36	0,38	0,64	0,34	0,27	0,33	0,32	0,51
KV	14,3	14,2	6,9	11,7	13,2	13,5	20,5	10,2	8,4	11,3	12,8	16,2

LAMPIRAN F

HASIL UJI KERAPUHAN ODT DOMPERIDONE

Formula	Replikasi	Berat awal (gram)	Berat akhir (gram)	Kerapuhan (%)	X□	SD	KV
I	I	1,98	1,97	0,51	0,64	0,26	39,70
	II	2,05	2,04	0,49			
	III	2,13	2,11	0,94			
II	I	2,06	2,04	0,97	1,12	0,29	25,84
	II	2,13	2,11	0,94			
	III	2,06	2,03	1,46			
III	I	2,06	2,05	0,49	0,32	0,28	86,62
	II	2,16	2,16	0,00			
	III	2,11	2,10	0,47			
IV	I	2,11	2,09	0,95	0,97	0,02	2,44
	II	2,01	1,99	1,00			
	III	2,05	2,03	0,98			

LAMPIRAN G

HASIL UJI WAKTU HANCUR ODT DOMPERIDONE

No.	Waktu Hancur ODT Domperidone (detik)											
	Formula I			Formula II			Formula III			Formula IV		
1	51	42	55	38	39	41	70	73	69	57	37	63
2	53	43	59	43	36	35	61	105	71	65	39	54
3	52	36	56	41	30	29	78	72	73	63	48	66
4	51	43	55	35	31	41	60	78	56	53	42	59
5	51	37	64	40	32	36	105	74	60	58	45	64
X□	51,6	40,2	57,8	39,4	33,6	36,4	74,8	80,4	65,8	59,2	42,2	61,2
SD	0,9	3,4	3,8	3,0	3,8	5,0	18,4	13,9	7,4	4,8	4,4	4,8
KV	1,7	8,5	6,6	7,7	11,3	13,7	24,6	17,3	11,2	8,1	10,5	7,8

LAMPIRAN H

HASIL UJI WAKTU PEMBASAHAN DAN RASIO ABSORBSI AIR ODT DOMPERIDONE

Formula I

Rep.	No.	Waktu Pembasahan dan Rasio Absorpsi Air			
		Wb	**Wa**	**Waktu Pembasahan (detik)**	**Rasio Absorpsi Air (%)**
I	1	95,6	135,2	45	41,42
	2	98,1	143,1	8	45,87
	3	95,6	175,6	48	83,68
	4	98,7	142,5	43	44,38
	5	95,0	140,2	49	47,58
	6	94,2	149,4	49	58,60
	X□	96,20	147,67	40,33	53,59
	SD	1,79	14,44	16,02	15,87
	KV	1,86	9,78	39,72	29,61
II	1	105,7	175,6	41	66,13
	2	108,0	186,0	47	72,22
	3	106,5	203,2	59	90,80
	4	105,8	166,5	37	57,37
	5	106,3	170,5	48	60,40
	6	107,6	163,8	52	52,23
	X□	106,65	177,60	47,33	66,52
	SD	0,95	14,79	7,81	13,77
	KV	0,89	8,33	16,51	20,69
III	1	105,5	153,1	69	45,12
	2	105,0	154,5	68	47,14
	3	105,0	152,6	64	45,33
	4	93,8	138,3	51	47,44
	5	104,8	153,5	56	46,47
	6	107,6	163,2	54	51,67
	X□	103,62	152,53	60,33	47,20
	SD	4,92	8,02	7,66	2,38
	KV	4,75	5,26	12,70	5,05

Keterangan: Wb=berat tablet sebelum terbasahi
Wa=berat tablet setelah terbasahi

Formula II

Rep.	No.	Waktu Pembasahan dan Rasio Absorpsi Air			
		Wb	**Wa**	**Waktu Pembasahan (detik)**	**Rasio Absorpsi Air (%)**
I	1	100,9	153,8	51	52,43
	2	102,2	181,1	40	77,20
	3	104,5	170,2	56	62,87
	4	105,6	180,8	52	71,21
	5	104,0	190,3	52	82,98
	6	104,0	160,2	52	54,04
	X□	103,53	172,73	50,50	66,79
	SD	1,69	13,90	5,43	12,44
	KV	1,64	8,05	10,76	18,63
II	1	111,5	181,0	60	62,33
	2	108,4	153,1	53	41,24
	3	107,8	185,0	52	71,61
	4	111,2	182,3	54	63,94
	5	111,7	172,8	43	54,70
	6	111,0	174,2	54	56,94
	X□	110,27	174,73	52,67	58,46
	SD	1,71	11,61	5,50	10,31
	KV	1,55	6,64	10,45	17,63
III	1	103,5	178,7	48	72,66
	2	103,8	193,7	53	86,61
	3	101,6	176,6	52	73,82
	4	104,2	197,8	57	89,83
	5	102,3	176,6	58	72,63
	6	102,7	180,9	59	76,14
	X□	103,02	184,05	54,50	78,61
	SD	0,99	9,29	4,23	7,62
	KV	0,96	5,05	7,76	9,69

Keterangan: Wb=berat tablet sebelum terbasahi
Wa=berat tablet setelah terbasahi

Formula III

Rep.	No.	Waktu Pembasahan dan Rasio Absorpsi Air			
		Wb	**Wa**	**Waktu Pembasahan (detik)**	**Rasio Absorpsi Air (%)**
I	1	103,2	172,2	63,0	66,86
	2	101,7	172,3	59,0	69,42
	3	101,5	176,6	52,0	73,99
	4	101,9	166,6	64,0	63,49
	5	102,9	185,8	72,0	80,56
	6	106,2	169,2	51,0	59,32
	X□	102,90	173,78	60,17	68,94
	SD	1,75	6,78	7,94	7,58
	KV	1,70	3,90	13,19	11,00
II	1	107,8	181,2	76	68,09
	2	109,5	176,2	66	60,91
	3	105,7	206,1	60	94,99
	4	106,2	192,0	68	80,79
	5	109,3	178,1	59	62,95
	6	110,0	200,5	68	82,27
	X□	108,08	189,02	66,17	75,00
	SD	1,81	12,47	6,21	13,25
	KV	1,68	6,60	9,39	17,66
III	1	104,8	159,5	84	52,19
	2	108,8	167,5	94	53,95
	3	101,2	155,8	62	53,95
	4	102,3	173,8	75	69,89
	5	99,8	157,4	84	57,72
	6	108,6	160,1	82	47,42
	X□	104,25	162,35	80,17	55,85
	SD	3,82	6,90	10,78	7,65
	KV	3,66	4,25	13,44	13,69

Keterangan: Wb=berat tablet sebelum terbasahi
Wa=berat tablet setelah terbasahi

Formula IV

Rep.	No.	Waktu Pembasahan dan Rasio Absorpsi Air			
		Wb	**Wa**	**Waktu Pembasahan (detik)**	**Rasio Absorpsi Air (%)**
I	1	104,0	198,1	71	90,48
	2	103,2	179,2	57	73,64
	3	104,8	183,9	56	75,48
	4	105,3	188,9	75	79,39
	5	106,2	190,1	60	79,00
	6	103,6	183,3	56	76,93
	X□	104,52	187,25	62,50	79,15
	SD	1,13	6,64	8,36	5,95
	KV	1,08	3,54	13,38	7,52
II	1	101,3	203,4	59	100,79
	2	97,0	174,0	50	79,38
	3	102,0	175,2	53	71,76
	4	101,5	175,5	60	72,91
	5	100,0	184,1	50	84,10
	6	100,3	184,3	59	83,75
	X□	100,35	182,75	55,17	82,12
	SD	1,81	11,11	4,71	10,53
	KV	1,80	6,08	8,53	12,83
III	1	106,0	174,4	89	64,53
	2	104,1	180,3	131	73,20
	3	100,8	176,0	95	74,60
	4	102,2	182,2	80	78,28
	5	103,0	180,5	80	75,24
	6	100,5	182,2	62	81,29
	X□	102,77	179,27	89,50	74,52
	SD	2,08	3,29	23,19	5,69
	KV	2,02	1,84	25,91	7,64

Keterangan: Wb=berat tablet sebelum terbasahi
Wa=berat tablet setelah terbasahi

LAMPIRAN I

HASIL UJI STABILITAS ODT DOMPERIDONE

No.	Waktu Hancur setelah 1 bulan penyimpanan (detik)											
	Formula I			Formula II			Formula III			Formula IV		
1	33	54	43	30	31	30	68	60	60	48	42	50
2	43	34	40	29	33	29	60	72	70	45	37	52
3	34	40	38	31	34	26	57	59	73	49	39	49
4	34	37	42	30	35	32	65	54	81	45	38	42
5	32	35	50	28	34	33	56	64	58	52	43	45
X□	35,2	40	42,6	29,6	33	30	61,2	61,8	68,4	47,8	40	47,6
SD	4,4	8,2	4,6	1,1	1,5	2,7	5,2	6,7	9,5	2,9	2,6	4,0
KV	12,6	20,4	10,7	3,9	4,5	9,1	8,4	10,9	13,9	6,2	6,5	8,5

No.	Waktu Pembasahan setelah 1 bulan penyimpanan (detik)											
	Formula I			Formula II			Formula III			Formula IV		
1	42	47	52	50	53	37	64	53	64	64	49	78
2	43	41	54	52	54	50	71	72	77	74	57	90
3	52	43	60	52	55	41	61	64	71	60	60	86
4	47	52	58	60	46	51	69	86	68	68	53	84
5	46	50	60	67	50	52	84	62	74	68	66	82
X□	45	38	52	54	56	55	55	56	72	65	62	72
SD	45,8	45,2	56,0	55,8	52,3	47,7	67,3	65,5	71,0	66,5	57,8	82,0
KV	3,5	5,4	3,8	6,5	3,7	7,0	10,0	12,0	4,6	4,7	6,2	6,3

LAMPIRAN J
HASIL UJI PENETAPAN KADAR TABLET DOMPERIDONE

Formula	Rep.	Abs.	C Sampel (µg/ml)	X□ W Tablet (mg)	W Sampel (mg)	C Teoritis (µg/ml)	Kadar (%)	X□	SD	KV (%)
I	1	0,262	8,17	97,25	100,2	8,24	99,11	102,80	4,03	3,92
	2	0,256	7,96	108,0	100,3	7,43	107,10			
	3	0,256	7,96	102,95	100,2	7,79	102,20			
II	1	0,255	7,92	103,67	100,2	103,67	100,2	103,07	1,87	1,81
	2	0,254	7,89	103,66	100,6	103,67	100,6			
	3	0,249	7,71	109,34	100,2	109,34	100,2			
III	1	0,264	8,24	102,25	100,7	7,88	104,58	104,72	1,64	1,56
	2	0,246	7,60	109,07	100,5	7,37	103,16			
	3	0,253	7,85	108,43	100,0	7,38	106,42			
IV	1	0,250	7,75	105,6	100,7	7,63	101,53	102,02	4,26	4,18
	2	0,263	8,20	104,47	100,6	7,70	106,50			
	3	0,246	7,60	103,54	100,4	7,76	98,03			
Pembanding 1	1	0,209	6,30	119,8	99,8	6,66	94,50	96,50	1,78	1,85
	2	0,211	6,37	123,4	100,3	6,50	97,95			
	3	0,214	6,47	121,1	101,0	6,67	97,04			
Pembanding 2	1	0,229	7,00	121,5	100,3	6,60	106,06	103,05	2,62	2,55
	2	0,213	6,44	125,4	99,7	6,36	101,24			
	3	0,216	6,55	124,6	100,1	6,43	101,84			

Keterangan: Pembanding 1 = tablet generik domperidone; Pembanding 2 = ODT domperidone dengan nama dagang

LAMPIRAN K

HASIL UJI DISOLUSI ODT DOMPERIDONE

Formula I

Rep.	t (menit)	Abs.	Kons. (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg.menit/mL)
I	0,5	0,167	4,82	4,3	43,73	1,08
	1	0,302	9,58	8,6	87,01	3,24
	2	0,338	10,85	9,8	98,55	9,19
	4	0,338	10,85	9,8	98,55	19,53
	6	0,339	10,89	9,8	98,87	19,56
	8	0,341	10,96	9,9	99,51	19,66
	10	0,338	10,85	9,8	98,55	19,63
	15	0,334	10,71	9,6	97,26	48,51
	20	0,335	10,75	9,7	97,58	48,28
	25	0,334	10,71	9,6	97,26	48,28
	30	0,333	10,68	9,6	96,94	48,12
					ΣAUC	285,09
					%ED	95,89
II	0,5	0,130	3,51	3,2	29,49	0,79
	1	0,235	7,22	6,5	60,64	2,41
	2	0,342	10,99	9,9	92,38	8,19
	4	0,356	11,49	10,3	96,53	20,23
	6	0,364	11,77	10,6	98,90	20,93
	8	0,361	11,66	10,5	98,01	21,09
	10	0,355	11,45	10,3	96,23	20,80
	15	0,355	11,45	10,3	96,23	51,53
	20	0,352	11,35	10,2	95,34	51,29
	25	0,352	11,35	10,2	95,34	51,06
	30	0,350	11,28	10,1	94,75	50,90
					ΣAUC	299,23
					%ED	93,13

Rep.	t (menit)	Abs.	Kons. (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg.menit/mL)
III	0,5	0,099	2,42	2,2	21,27	0,54
	1	0,270	8,45	7,6	74,43	2,45
	2	0,309	9,83	8,8	86,55	8,23
	4	0,329	10,53	9,5	92,77	18,33
	6	0,337	10,82	9,7	95,26	19,22
	8	0,325	10,39	9,4	91,53	19,09
	10	0,325	10,39	9,4	91,53	18,71
	15	0,316	10,08	9,1	88,73	46,05
	20	0,331	10,60	9,5	93,39	46,53
	25	0,326	10,43	9,4	91,84	47,32
	30	0,331	10,60	9,5	93,39	47,32
					ΣAUC	273,78
					%ED	89,30

Formula II

Rep.	t (menit)	Abs.	Kons. (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg.menit/mL)
	0,5	0,200	5,98	5,4	52,54	1,35
	1	0,318	10,15	9,1	89,12	3,63
	2	0,347	11,17	10,1	98,12	9,59
	4	0,350	11,28	10,1	99,05	20,20
	6	0,353	11,38	10,2	99,98	20,39
	8	0,352	11,35	10,2	99,67	20,45
I	10	0,346	11,13	10,0	97,81	20,23
	15	0,348	11,20	10,1	98,43	50,26
	20	0,340	10,92	9,8	95,95	49,79
	25	0,345	11,10	10,0	97,50	49,55
	30	0,346	11,13	10,0	97,81	50,02
					ΣAUC	295,46
					%ED	96,13
	0,5	0,167	4,82	4,3	42,66	1,08
	1	0,277	8,70	7,8	77,06	3,04
	2	0,338	10,85	9,8	96,14	8,80
	4	0,348	11,20	10,1	99,27	19,85
	6	0,350	11,28	10,1	99,89	20,23
	8	0,343	11,03	9,9	97,70	20,07
II	10	0,339	10,89	9,8	96,45	19,72
	15	0,340	10,92	9,8	96,77	49,07
	20	0,341	10,96	9,9	97,08	49,23
	25	0,340	10,92	9,8	96,77	49,23
	30	0,335	10,75	9,7	95,20	48,75
					ΣAUC	289,08
					%ED	94,86
	0,5	0,161	4,60	4,1	39,40	1,04
	1	0,299	9,48	8,5	81,08	3,17
	2	0,338	10,85	9,8	92,87	9,15
	4	0,361	11,66	10,5	99,81	20,26
	6	0,354	11,42	10,3	97,70	20,77
	8	0,348	11,20	10,1	95,89	20,36
III	10	0,349	11,24	10,1	96,19	20,20
	15	0,335	10,75	9,7	91,96	49,47
	20	0,332	10,64	9,6	91,05	48,12
	25	0,332	10,64	9,6	91,05	47,88
	30	0,330	10,57	9,5	90,45	47,72
					ΣAUC	288,13
					%ED	91,32

Formula III

Rep.	t (menit)	Abs.	Kons. (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg.menit/mL)
	0,5	0,131	3,54	3,2	30,51	0,80
	1	0,227	6,93	6,2	59,67	2,36
	2	0,343	11,03	9,9	94,91	8,08
	4	0,352	11,35	10,2	97,64	20,14
	6	0,353	11,38	10,2	97,94	20,45
	8	0,357	11,52	10,4	99,16	20,61
I	10	0,352	11,35	10,2	97,64	20,58
	15	0,350	11,28	10,1	97,03	50,90
	20	0,352	11,35	10,2	97,64	50,90
	25	0,340	10,92	9,8	94,00	50,10
	30	0,341	10,96	9,9	94,30	49,23
					ΣAUC	294,15
					%ED	93,76
	0,5	0,124	3,30	3,0	28,77	0,74
	1	0,281	8,84	8,0	77,12	2,73
	2	0,338	10,85	9,8	94,67	8,86
	4	0,340	10,92	9,8	95,29	19,60
	6	0,345	11,10	10,0	96,83	19,82
	8	0,348	11,20	10,1	97,75	20,07
II	10	0,344	11,06	10,0	96,52	20,04
	15	0,338	10,85	9,8	94,67	49,31
	20	0,336	10,78	9,7	94,06	48,67
	25	0,340	10,92	9,8	95,29	48,83
	30	0,339	10,89	9,8	94,98	49,07
					ΣAUC	287,75
					%ED	92,98
	0,5	0,136	3,72	3,3	31,47	0,84
	1	0,223	6,79	6,1	57,44	2,37
	2	0,331	10,60	9,5	89,68	7,83
	4	0,351	11,31	10,2	95,65	19,72
	6	0,360	11,63	10,5	98,34	20,64
	8	0,363	11,73	10,6	99,24	21,03
III	10	0,364	11,77	10,6	99,53	21,15
	15	0,362	11,70	10,5	98,94	52,80
	20	0,356	11,49	10,3	97,15	52,17
	25	0,360	11,63	10,5	98,34	52,01
	30	0,360	11,63	10,5	98,34	52,33
					ΣAUC	302,89
					%ED	94,87

Formula IV

Rep.	t (menit)	Abs.	Kons. (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg.menit/mL)
	0,5	0,143	3,97	3,6	35,18	0,89
	1	0,247	7,64	6,9	64,56	2,61
	2	0,335	10,75	9,7	90,81	8,27
	4	0,346	11,13	10,0	94,09	19,69
	6	0,350	11,28	10,1	95,28	20,17
	8	0,344	11,06	10,0	93,49	20,10
I	10	0,346	11,13	10,0	94,09	19,98
	15	0,344	11,06	10,0	93,49	49,94
	20	0,343	11,03	9,9	93,19	49,71
	25	0,339	10,89	9,8	92,00	49,31
	30	0,338	10,85	9,8	91,70	48,91
					ΣAUC	289,59
					%ED	95,08
	0,5	0,160	4,57	4,1	38,61	1,03
	1	0,274	8,59	7,7	72,61	2,96
	2	0,343	11,03	9,9	93,19	8,83
	4	0,363	11,73	10,6	99,16	20,49
	6	0,363	11,73	10,6	99,16	21,12
	8	0,365	11,80	10,6	99,75	21,18
II	10	0,362	11,70	10,5	98,86	21,15
	15	0,356	11,49	10,3	97,07	52,17
	20	0,350	11,28	10,1	95,28	51,22
	25	0,353	11,38	10,2	96,17	50,98
	30	0,356	11,49	10,3	97,07	51,45
					ΣAUC	302,58
					%ED	94,70
	0,5	0,116	3,02	2,7	27,69	0,68
	1	0,206	6,19	5,6	56,85	2,07
	2	0,291	9,19	8,3	84,40	6,92
	4	0,330	10,57	9,5	97,04	17,79
	6	0,336	10,78	9,7	98,98	19,22
	8	0,333	10,68	9,6	98,01	19,31
III	10	0,332	10,64	9,6	97,69	19,18
	15	0,327	10,46	9,4	96,07	47,48
	20	0,327	10,46	9,4	96,07	47,09
	25	0,336	10,78	9,7	98,98	47,80
	30	0,323	10,32	9,3	94,77	47,48
					ΣAUC	275,02
					%ED	93,52

Pembanding 1

Rep.	t (menit)	Abs.	Kons. (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg.menit/mL)
	0,5	0,167	4,82	4,3	45,86	1,08
	1	0,204	6,12	5,5	58,30	2,46
	2	0,306	9,72	8,7	92,59	7,13
	4	0,312	9,93	8,9	94,60	17,69
	6	0,322	10,29	9,3	97,97	18,20
	8	0,334	10,71	9,6	102,00	18,90
I	10	0,321	10,25	9,2	97,63	18,87
	15	0,327	10,46	9,4	99,65	46,61
	20	0,307	9,76	8,8	92,92	45,50
	25	0,313	9,97	9,0	94,94	44,39
	30	0,319	10,18	9,2	96,96	45,34
					ΣAUC	266,16
					%ED	93,88
	0,5	0,117	3,05	2,7	28,03	0,69
	1	0,240	7,39	6,7	67,93	2,35
	2	0,277	8,70	7,8	79,93	7,24
	4	0,310	9,86	8,9	90,63	16,71
	6	0,324	10,36	9,3	95,17	18,20
	8	0,328	10,50	9,4	96,47	18,77
II	10	0,320	10,22	9,2	93,88	18,64
	15	0,310	9,86	8,9	90,63	45,18
	20	0,326	10,43	9,4	95,82	45,66
	25	0,318	10,15	9,1	93,23	46,29
	30	0,322	10,29	9,3	94,52	45,97
					ΣAUC	265,70
					%ED	90.42
	0,5	0,148	4,15	3,7	38,44	0,93
	1	0,227	6,93	6,2	64,31	2,49
	2	0,248	7,67	6,9	71,18	6,57
	4	0,285	8,98	8,1	83,29	14,99
	6	0,327	10,46	9,4	97,04	17,50
	8	0,328	10,50	9,4	97,37	18,87
III	10	0,314	10,00	9,0	92,79	18,45
	15	0,325	10,39	9,4	96,39	45,89
	20	0,306	9,72	8,7	90,17	45,26
	25	0,319	10,18	9,2	94,42	44,78
	30	0,326	10,43	9,4	96,72	46,37
					ΣAUC	262,11
					%ED	90,04

Pembanding 2

Rep.	t (menit)	Abs.	Kons. (µg/ml)	Wt (mg)	% obat terlepas	AUC (µg.menit/mL)
	0,5	0,145	4,04	3,6	34,28	0,91
	1	0,284	8,95	8,1	75,91	2,92
	2	0,342	10,99	9,9	93,28	8,97
	4	0,351	11,31	10,2	95,98	20,07
	6	0,358	11,56	10,4	98,08	20,58
	8	0,348	11,20	10,1	95,08	20,49
I	10	0,333	10,68	9,6	90,59	19,69
	15	0,343	11,03	9,9	93,58	48,83
	20	0,350	11,28	10,1	95,68	50,18
	25	0,341	10,96	9,9	92,99	50,02
	30	0,342	10,99	9,9	93,28	49,39
					ΣAUC	292,06
					%ED	91,79
	0,5	0,196	5,84	5,3	51,91	1,31
	1	0,208	6,26	5,6	55,68	2,72
	2	0,291	9,19	8,3	81,72	6,96
	4	0,352	11,35	10,2	100,86	18,48
	6	0,346	11,13	10,0	98,98	20,23
	8	0,338	10,85	9,8	96,47	19,79
II	10	0,336	10,78	9,7	95,84	19,47
	15	0,341	10,96	9,9	97,41	48,91
	20	0,331	10,60	9,5	94,27	48,51
	25	0,334	10,71	9,6	95,21	47,96
	30	0,326	10,43	9,4	92,70	47,56
					ΣAUC	281,91
					%ED	92,82
	0,5	0,130	3,51	3,2	31,02	0,79
	1	0,241	7,43	6,7	65,64	2,46
	2	0,341	10,96	9,9	96,84	8,27
	4	0,359	11,59	10,4	102,45	20,30
	6	0,348	11,20	10,1	99,02	20,52
	8	0,352	11,35	10,2	100,27	20,30
III	10	0,347	11,17	10,1	98,71	20,26
	15	0,337	10,82	9,7	95,59	49,47
	20	0,344	11,06	10,0	97,77	49,23
	25	0,312	9,93	8,9	87,79	47,24
	30	0,331	10,60	9,5	93,72	46,21
					ΣAUC	285,05
					%ED	93,30

LAMPIRAN L

CONTOH PERHITUNGAN

Contoh perhitungan indeks kompresibilitas:

Formula I :

Berat gelas = 117,3718 g (W_1)

Berat gelas + granul = 163,5685 g (W_2)

V_1 = 100 ml, V_2 = 85 ml

$$\text{Bj nyata} = \frac{(W_2 - W_1)}{V_1} = \frac{(163{,}5685 - 117{,}3718)}{100} = 0{,}4620 \text{ g/ml}$$

$$\text{Bj mampat} = \frac{(W_2 - W_1)}{V_2} = \frac{(163{,}5685 - 117{,}3718)}{85} = 0{,}5435 \text{ g/ml}$$

$$\%\ Carr's\ Index = \left(1 - \frac{Bj.nyata}{Bj.mampat}\right) \times 100\% = 15\%$$

$$Hausner\ Ratio = \frac{bjmampat}{bjnyata} = 1{,}18$$

Contoh perhitungan akurasi & presisi:

Kons. (%)	Massa (mg)	Abs.	Kons. (µg/ml)	Teoritis (µg/ml)	Perolehan Kembali (%)
100	100,4	0,261	8,13	8,03	101,30

Absorbansi = 0,261 → y = 0,0283x + 0,0306

Konsentrasi sampel (x) = 8,13 ppm

Berat domperidone = 70 mg

Berat matriks = 630,2 mg

Berat sampel = 100,4 mg

Konsentrasi teoritis $= \frac{W\ sampel}{(W\ domperidone\ + W\ matriks)} \times W_{domperidone} \times FP$

$= \frac{100,4}{(70+630,2)} \times 70 \times 10^3 \times \left(\frac{1}{250} \times \frac{2}{10}\right)$

$=$ 8,03 ppm

% Perolehan Kembali $= \frac{\text{konsentrasi sampel}}{\text{konsentrasi teoritis}} \times 100\%$

$= \frac{8,13}{8,03} \times 100\%$

$=$ 101,3%

% KV $= \frac{SD}{\bar{X}} \times 100\%$

$= \frac{1,24}{100,51} \times 100\%$

$=$ 1,24%

Contoh perhitungan penetapan kadar:

Abs.	Kons. Sampel (µg/ml)	W Tablet Rata-rata (mg)	W Sampel (mg)	Kons. Teoritis (µg/ml)	Kadar (%)
0,262	8,17	97,25	100,2	8,24	99,11

Absorbansi = 0,262 → y = 0,0283x + 0,0306

Konsentrasi sampel (x) = 8,17 ppm

Berat tablet rata-rata = 97,25 g

Berat sampel = 100,2 mg

Berat Domperidone = 10 mg

Konsentrasi teoritis $= \frac{W\ sampel}{W\ tablet\ rata-rata} \times W_{domperidone} \times FP$

$= \frac{100,2}{97,25} \times 10 \times 10^3 \times \left(\frac{1}{250} \times \frac{2}{10}\right) =$ 8,24 ppm

% Perolehan Kembali $= \frac{\text{konsentrasi sampel}}{\text{konsentrasi teoritis}} \times 100\%$

$$= \frac{9,17}{9,24} \times 100\% = 99,11\%$$

$$\%\ KV = \frac{SD}{\overline{X}} \times 100\%$$

$$= \frac{4,93}{102,80} \times 100\%$$

$$= 4,92\%$$

Contoh perhitungan % obat terlepas:

Formula I replikasi 1 pada t = 30 menit

Absorbansi = 0,333 → y = 0,0283x + 0,0306

Csampel (x) = 10,68 µg/ml

Wt = (900/1000 x konsentrasi sampel)

= (900/1000 x 10,68)

= 9,6 mg

$$\%\ \text{Obat Terlepas} = \frac{Wt}{\frac{PK}{100} \times dosis} \times 100\%$$

Formula I replikasi 1 pada t = 30 menit

$$\%\ \text{Obat Terlepas} = \frac{9,6}{\frac{99,11}{100} \times 10} \times 100\% = 96,94\%$$

Contoh perhitungan AUC pada disolusi:

Rumus:

Formula I replikasi 1

tn-1 = 30 menit Wtn-1 = 9,6 mg

tn = 25 menit Wtn = 9,6 mg

AUC = $\frac{9,6+9,6}{2} \times (30-25)$ = 48,12

Luas persegi panjang = 30 x penetapan kadar x dosis

= 30 x 99,11% x 10 mg

= 297,32

% ED Formula I replikasi 1 = (∑ AUC / luas persegi panjang) x 100%

= (285,09/297,32) x 100%

= 95,89 %

LAMPIRAN M

SERTIFIKAT ANALISIS BAHAN

DOMPERIDONE

VASUDHA PHARMA CHEM. LTD

VASUDHA PHARMA CHEM LIMITED
78/A, VENGAL RAO NAGAR, HYDERABAD-38
ANDHRA PRADESH, INDIA
PHONE:+91-40-2381 2046, 2371 1717, FAX: 91-40-2381 1576
E-MAIL: vasudha@vasudhaphrma.com, Website: www.vasudhapharma.com

CERTIFICATE OF ANALYSIS

Name of the product	:	DOMPERIDONE	Page No.	:	1 of 2
Batch Number	:	BDOM/1106090	A.R.No	:	BDOM/11090
Manufacturing Date	:	JUN 2011	Expiry Date	:	MAY 2016
Dispatch Quantity	:	30.0 Kg	Analyzed on	:	18/06/2011
Customer Name/ code	:	PT Taterasa			

S.No	TEST		RESULT	SPECIFICATION
1.0	CHARACTERS			
1.1	Appearance		A white powder	A white or almost white powder.
1.2	Solubility		Complies	Practically insoluble in water, soluble in dimethyl formamide,slightly soluble in alcohol and in methanol
2.0	Identification			
	FIRST IDENTIFICATION			
	A	Melting Point (°)	244.5	244 to248
	B	IR Identification (KBr disc)	Complies	The spectrum obtained with the substance to be examined correspond in position and relative size to those in the spectrum obtained with Domperidone reference standard(Working standard)
	SECOND IDENTIFICATION			
	C	Thin layer chromatography (TLC)	Complies	The principal spot in the chromatogram obtained with the test solution is similar in position and size to the principal spot in the chromatogram obtained with reference solution(a)
	D	Test for non-nitrogen substituted barbiturates	Complies	A violet blue colour and precipitate produces
3.0	TESTS			
3.1	Appearance of solution		Complies	The solution should be clear and not more intensely coloured than reference solution Y_6

RELEASE

PREPARED BY: 21/06/2011 CHECKED BY : 21/06/2011 APPROVED BY: 21/06/2011

Works

M/s. VASUDHA PHARMA CHEM LIMITED, Unit-II, Plot No: 79, J.N.Pharma City, Thanam Village, Parawada Mandalam, Visakhapatnam – 531 021, Andhra Pradesh, India.

VASUDHA PHARMA CHEM. LTD

VASUDHA PHARMA CHEM LIMITED
78/A, VENGAL RAO NAGAR, HYDERABAD-38
ANDHRA PRADESH, INDIA
PHONE:+91-40-2381 2046, 2371 1717, FAX: 91-40-2381 1576
E-MAIL.: vasudha@vasudhaphrma.com, Website: www.vasudhapharma.com

Name of the product	:	DOMPERIDONE	Page No.	:	2 of 2
Batch Number	:	BDOM/1106090	A.R.No	:	BDOM/11090
Manufacturing Date	:	JUN 2011	Expiry Date	:	MAY 2016
Dispatch Quantity	:	30.0 Kg	Analyzed on	:	18/06/2011
Customer Name/ code	:	PT Taterasa			

S.No	TEST	RESULT	SPECIFICATION
3.2	Heavy metals (ppm)	Less than 20	Not more than 20
3.3	Loss on drying(%,w/w)	0.34	Not more than 0.5
3.4	Sulphated Ash(%,w/w)	0.06	Not more than 0.1
3.5	Assay (By titrimetry, %w/w, on dried basis)	99.53	Not less than 99.0 and Not more than 101.0
3.6	Related substances (By HPLC, %)		
	Impurity-A	0.06	Not more than 0.25
	Impurity-B	Not detected	Not more than 0.25
	Impurity-C	Not detected	Not more than 0.25
	Impurity-D	0.14	Not more than 0.25
	Impurity-E	Not detected	Not more than 0.25
	Impurity-F	Not detected	Not more than 0.25
	Unspecified impurities	Not detected	Not more than 0.10
	Total impurity	0.19	Not more than 0.50

REMARKS: The material complies as per the BP specification.

QUALITY ASSURANCE Sign Dt. 21/06/11 RELEASED

PREPARED BY: 21/06/2011 **CHECKED BY :** 21/06/2011 **APPROVED BY:** 21/06/11

Works

M/s. VASUDHA PHARMA CHEM LIMITED, Unit-II, Plot No: 79, J.N.Pharma City, Thanam Village, Parawada Mandalam, Visakhapatnam – 531 021, Andhra Pradesh, India.

JRS PHARMA JRS THE EXCIPIENT FAMILY

VIVASOL®

Croscarmellose Sodium Ph. Eur., NF, JP

CERTIFICATE OF ANALYSIS

Batch-no.: 3201014100
Re-evaluation date: November 2015
Manufacturing date: November 2011
Manufacturing site: Pirna, Germany

Description	Almost white, very hygroscopic powder; practically insoluble in acetone, ethanol, ether and toluene.

Standards	Specification	Batch Result	Reference
Particle size (retained on air jet sieve)			T226F (MCW)
> 75 µm (200 mesh)	max. 2 %	< 2 %*	
> 45 µm (325 mesh)	max. 10 %	< 10 %*	

Pharmacopoeial test items	Specification	Batch Result	Reference
Identification (A, B, C), (1, 2, 3)	passes	passes*	Ph. Eur., NF, JP
Degree of Substitution	0.60 – 0.85	0.75 *	Ph. Eur., NF, JP
Loss on drying	max. 10.0 %	5.6 %	Ph. Eur., NF, JP
pH	5.0 - 7.0	6.1	Ph. Eur., USP, JP
Content of water-soluble material	1.0 -10.0 %	4.7 %	Ph. Eur., NF, JP
Sulphated ash	14.0 – 28.0 %	passes*	Ph. Eur., JP
Settling volume	10.0 – 30.0 ml	15.0 ml	Ph. Eur., NF, JP
Sodium chloride and Sodium glycolate	max. 0.5 %	< 0.5 %*	Ph. Eur., NF, JP
Heavy metals	max. 10 ppm	< 10 ppm*	T CC 043 (CHP)
Arsenic	max. 2 ppm	< 2 ppm*	T CC 043 (CHP)
Residue of Methanol	max. 1.0 %	< 1.0 %*	T CC 019 (CHP)
Total aerobic microbial count	< 100 CFU / g	< 100 CFU / g*	Ph. Eur., USP
Fungi / molds and yeasts	< 20 CFU / g	< 20 CFU / g*	Ph. Eur., USP
E. coli, Pseudomonas aeruginosa	absent in 10 g	absent*	Ph. Eur., USP
Staph. aureus, Salmonella spec.	absent in 10 g	absent*	Ph. Eur., USP

* Results reported are expected results based on periodic testing.

The batch described by this certificate meets the requirements of Ph. Eur., NF and JP monographs for "Croscarmellose Sodium" current edition. It is released on the basis of the results ascertained.

The raw materials, manufacturing process, and product do not contain any of the solvents listed in the Residual Solvents (Ph. Eur.<5.4>, USP<467>) except for Methanol limited to max. 1.0%.

This product may contain raw materials derived from unauthorized genetically modified cotton and is not suitable for the production or marketing of food or dietary supplements in the EC.

Storage recommendation: Protect from excessive heat and moisture.
Keep containers closed.

November 25, 2011
AB: 21142739
VSOL P09

Mathias Winkelmann
QUALITY CONTROL
CHP Carbohydrate Pirna

Worldwide headquarters
JRS PHARMA GMBH & CO. KG
73494 Rosenberg (Germany) · Holzmühle 1
Phone: + 49 (0) 7967 / 152 312
Fax: + 49 (0) 7967 / 152 345
info@jrspharma.de · www.jrspharma.de · www.jrs.de
Customer Service: + 49 (0) 7967 / 152 312

USA + Canada
JRS PHARMA LP
2981 Route 22, Suite 1 · Patterson, NY 12563-2359, USA
Toll-Free (USA): + 1 (800) 431 2457
Phone: + 1 (845) 878 3414 · Fax: + 1 (845) 878 3484
info@jrspharma.com · www.jrspharma.com
Customer Service: +1 (845) 878 3414



GELITA

ASIA PACIFIC AFRICA

Certificate of Analysis

CLIENT:

LOT NO: 5023174
QUANTITY: 1500 kg
ORDER NO: 045/05

COUNTRY: Indonesia
PRODUCT GRADE: HALAL EXPORT 150/30

PHYSICAL - CHEMICAL	RESULTS	METHOD
BLOOM (6.66%)	158 g	LAB003
pH 1.0%	4.96	LAB006
COLOUR IN SOLUTION	8 Pale Yellow	LAB004B
MOISTURE	11.19 %	LAB012
IGNITION RESIDUE	1.32 %	LAB011

MICROBIOLOGICAL

TOTAL COUNT	<100 /g	LAB021
TOTAL COLIFORMS	ABSENT /g	LAB022
ESCHERICHIA COLI	ABSENT /g	LAB024
SALMONELLA SP	ABSENT /25g	LAB023

SPECIAL TESTS

CLARITY	12.3 NTU	LAB005
SO2 DIRECT	mg/kg	LAB009B

BRATACO
IMPORTER
MANUFACTURER
DISTRIBUTOR

BRATACO
IMPORTER
MANUFACTURER
DISTRIBUTOR

* This product as specified complies with the Australian and New Zealand Food Standards Code ... December 2000

Darryn Gear
Quality Control Leader
DATE: 01/Mar/...
FAX: 64-3-384-3231

*Date of Manufacture: 1st digit of Lot number = year of manufacture, 2nd, 3rd digit = month of manufacture
*Best Before: When stored in a cool, dry area there should be no major changes in product properties for a 5 year period

Edible Gelatine Pharmaceutical Gelatine Photographic Gelatine GELITA Hydrolysates Instant Gelatine Special Gelatine

GELITA NZ Ltd. • 139-145 Connal Street, Christchurch 2, New Zealand
P.O. Box 19-542, Wooleton, Christchurch
Phone +64 3 384 3092 • Fax +64 3 384 3091

www.GELITA.com

MANITOL

ROQUETTE

LC 1 EELA CERTIFICATE OF ANALYSIS / COMPLIANCE

PAGE 1

PT SIGNA HUSADA
JALAN DAAN MOGOT KM 17
JAKARTA 11840
INDONESIA

PEARLITOL 160 C

CUSTOMER.... SIGNA HUSADA/INDONES

450001 D

INVOICE..... MD758A1
TONNAGE..... 18.000 KG
CONTRACT.... F55433L
ORDER....... P.O.100002538
BATCH....... E611T
MANUF&TESTED 14 APRIL 2011

EXPIRY DATE. 01 MAY 2016

E.P./U.S.P.

DESCRIPTION WHITE CRYSTALLINE POWDER
ODOURLESS, SWEET TASTE

MEANING TESTED = ANALYZED
MONITORED = MONITORING PLAN
GUARANTEED = COMPLIANCE DATA

APPEARANCE		CONFORM	TESTED
APPEARANCE IN SOLUTION		CONFORM	TESTED
LOSS ON DRYING	%	0,05	TESTED
INFRA-RED		CONFORM	TESTED
MELTING POINT	DEG	166	TESTED
START OF MELTING	DEG	166	TESTED
END OF MELTING	DEG	167	TESTED
SPECIFIC ROTATION(BORATE)	DEG.	+ 23,6	TESTED
SPECIFIC ROT.MOLYBDATE	DEG	+ 140,1	TESTED
CONDUCTIVITY	MICROS/C	1,0	TESTED
REDUCING SUGARS	*(USP)	CONFORM	TESTED
D-MANNITOL BY HPLC	%	99,2	TESTED

ROQUETTE FRERES, 1, RUE DE LA HAUTE LOGE, 62136 LESTREM FRANCE
... has an electronic signature

LAMPIRAN N

TABEL UJI

TABEL DISTRIBUSI F UNTUK 5% DAN 1%

Baris atas untuk taraf signifikan 5%
Baris bawah untuk taraf signifikan 1%

V_2 = dk penyebut	V_1 = dk pembilang																						
	1	2	3	4	5	6	7	8	9	10	11	12	14	16	20	24	30	40	50	75	100	200	500	∞
1	161	200	216	225	230	234	237	239	241	242	243	244	245	246	248	249	250	251	252	253	253	254	254	254
	4052	4999	5403	5625	5764	5859	5928	5961	6022	6056	6082	6106	6142	61,69	6208	6234	6258	6286	6302	6323	6334	6352	6361	6366
2	18,51	19,00	19,16	19,25	19,30	19,33	19,36	19,37	19,38	19,39	19,40	19,41	19,42	19,43	19,44	19,45	19,46	19,47	19,47	19,48	19,49	19,49	19,50	19,50
	98,49	99,01	99,17	99,25	99,30	99,33	99,34	99,36	97,38	99,40	99,41	99,42	99,43	99,44	99,45	99,46	99,47	99,48	99,48	99,49	99,49	99,49	99,50	99,50
3	10,13	9,55	9,28	9,12	9,01	8,94	8,88	8,84	8,81	8,78	8,76	8,74	8,71	8,69	8,66	8,64	8,62	8,60	8,58	8,57	8,56	8,54	8,54	8,53
	34,12	30,81	29,46	28,71	28,24	27,91	27,67	27,49	27,34	27,23	27,13	27,05	26,92	26,83	26,69	26,60	26,50	26,41	26,30	26,27	26,23	26,18	26,14	26,12
4	7,71	6,94	6,59	6,39	6,26	6,16	6,09	6,04	6,00	5,96	5,93	5,91	5,87	5,84	5,80	5,77	5,74	5,71	5,70	5,68	5,66	5,65	5,64	5,63
	21,20	18,00	16,69	15,98	15,52	15,21	14,98	14,80	14,66	14,54	14,45	14,37	14,24	14,15	14,02	13,93	13,83	13,74	13,69	13,61	13,57	13,52	13,48	13,46
5	6,61	5,79	5,41	5,19	5,05	4,95	4,88	4,82	4,78	4,74	4,70	4,68	4,64	4,60	4,56	4,53	4,50	4,46	4,44	4,42	4,40	4,38	4,37	4,36
	16,26	13,27	12,06	11,39	10,97	10,67	10,45	10,27	10,15	10,05	9,96	9,89	9,77	9,68	9,55	9,47	9,38	9,29	9,24	9,17	9,13	9,07	9,04	9,02
6	5,99	5,14	4,76	4,53	4,39	4,28	4,21	4,15	4,10	4,06	4,03	4,00	3,96	3,92	3,87	3,84	3,81	3,77	3,75	3,72	3,71	3,69	3,68	3,67
	13,74	10,92	9,78	9,15	8,75	8,47	8,26	8,10	7,98	7,87	7,79	7,72	7,60	7,52	7,39	7,31	7,23	7,14	7,09	7,02	6,99	6,94	6,90	6,88
7	5,59	4,74	4,35	4,12	3,97	3,87	3,79	3,73	3,68	3,63	3,60	3,57	3,52	3,49	3,44	3,41	3,38	3,34	3,32	3,29	3,28	3,25	3,24	3,23
	12,25	9,55	8,45	7,85	7,46	7,19	7,00	6,84	6,71	6,62	6,54	6,47	6,35	6,27	6,15	6,07	5,98	5,90	5,85	5,78	5,75	5,70	5,67	5,65
8	5,32	4,46	4,07	3,84	3,69	3,58	3,50	3,44	3,39	3,34	3,31	3,28	3,23	3,20	3,15	3,12	3,08	3,05	3,03	3,00	2,98	2,96	2,94	2,93
	11,26	8,65	7,59	7,01	6,63	6,37	6,19	6,03	5,91	5,82	5,74	5,67	5,56	5,48	5,36	5,28	5,20	5,11	5,06	5,00	4,96	4,91	4,88	4,86
9	5,12	4,26	3,86	3,63	3,48	3,37	3,29	3,23	3,18	3,13	3,10	3,07	3,02	2,98	2,93	2,90	2,86	2,82	2,80	2,77	2,76	2,73	2,72	2,71
	10,56	8,02	6,99	6,42	6,06	5,80	5,62	5,47	5,35	5,26	5,18	5,11	5,00	4,92	4,80	4,73	4,61	4,56	4,51	4,45	4,41	4,36	4,33	4,34

F

V_2 = dk penyebut	V_1 = dk pembilang																						
	1	2	3	4	5	6	7	8	9	10	11	12	14	16	20	24	30	40	50	75	100	200	500	∞
10	4,96	4,10	3,71	3,48	3,33	3,22	3,14	3,07	3,02	2,97	2,94	2,91	2,86	2,82	2,77	2,74	2,70	2,67	2,64	2,61	2,59	2,56	2,55	2,54
	10,04	7,56	6,55	5,99	5,64	5,39	5,21	5,06	4,95	4,85	4,78	4,71	4,60	4,52	4,41	4,33	4,25	4,17	4,12	4,05	4,01	3,96	3,93	3,91
11	4,84	3,98	3,59	3,36	3,20	3,09	3,01	2,95	2,90	2,86	2,82	2,79	2,74	2,70	2,65	2,61	2,57	2,53	2,50	2,47	2,45	2,42	2,41	2,40
	9,65	7,20	6,22	5,67	5,32	5,07	4,88	4,74	4,63	4,54	4,46	4,40	4,29	4,21	4,10	4,02	3,94	3,86	3,80	3,74	3,70	3,66	3,62	3,60
12	4,75	3,88	3,49	3,26	3,11	3,00	2,92	2,85	2,80	2,76	2,72	2,69	2,64	2,60	2,54	2,50	2,46	2,42	2,40	2,36	2,35	2,32	2,31	2,30
	9,33	6,93	5,95	5,41	5,06	4,82	4,65	4,50	4,39	4,30	4,22	4,16	4,05	3,98	3,86	3,78	3,70	3,61	3,56	3,49	3,46	3,41	3,38	3,36
13	4,67	3,80	3,41	3,18	3,02	2,92	2,84	2,77	2,72	2,67	2,63	2,60	2,55	2,51	2,46	2,42	2,38	2,34	2,32	2,28	2,26	2,24	2,22	2,21
	9,07	6,70	5,74	5,20	4,86	4,62	4,44	4,30	4,19	4,10	4,02	3,96	3,85	3,78	3,67	3,59	3,51	3,42	3,37	3,30	3,27	3,21	3,18	3,16
14	4,60	3,74	3,34	3,11	2,96	2,85	2,77	2,70	2,65	2,60	2,56	2,53	2,48	2,44	2,39	2,35	2,31	2,27	2,24	2,21	2,19	2,16	2,14	2,13
	8,86	6,51	5,56	5,03	4,69	4,46	4,28	4,14	4,03	3,94	3,86	3,80	3,70	3,62	3,51	3,43	3,34	3,26	3,21	3,14	3,11	3,06	3,02	3,00
15	4,54	3,68	3,29	3,06	2,90	2,79	2,70	2,64	2,59	2,55	2,51	2,48	2,43	2,39	2,33	2,29	2,25	2,21	2,18	2,15	2,12	2,10	2,08	2,07
	8,68	6,36	5,42	4,89	4,56	4,32	4,14	4,00	3,89	3,80	3,73	3,67	3,56	3,48	3,36	3,29	3,20	3,12	3,07	3,00	2,97	2,92	2,89	2,87
16	4,49	3,63	3,24	3,01	2,85	2,74	2,66	2,59	2,54	2,49	2,45	2,42	2,37	2,33	2,28	2,24	2,20	2,16	2,13	2,09	2,07	2,04	2,02	2,01
	8,53	6,23	5,29	4,77	4,44	4,20	4,03	3,89	3,78	3,69	3,61	3,55	3,45	3,37	3,25	3,18	3,10	3,01	2,96	2,89	2,86	2,80	2,77	2,75
17	4,45	3,59	3,20	2,96	2,81	2,70	2,62	2,55	2,50	2,45	2,41	2,38	2,33	2,29	2,23	2,19	2,15	2,11	2,08	2,04	2,02	1,99	1,97	1,96
	8,40	6,11	5,18	4,67	4,34	4,10	3,93	3,79	3,68	3,59	3,52	3,45	3,35	3,27	3,16	3,08	3,00	2,92	2,86	2,79	2,76	2,70	2,67	2,65
18	4,41	3,55	3,16	2,93	2,77	2,66	2,58	2,51	2,46	2,41	2,37	2,34	2,29	2,25	2,19	2,15	2,11	2,07	2,04	2,00	1,98	1,95	1,93	1,92
	8,28	6,01	5,09	4,58	4,25	4,01	3,85	3,71	3,60	3,51	3,44	3,37	3,27	3,19	3,07	3,00	2,91	2,83	2,78	2,71	2,68	2,62	2,59	2,57
19	4,38	3,52	3,13	2,90	2,74	2,63	2,55	2,48	2,43	2,38	2,34	2,31	2,26	2,21	2,15	2,11	2,07	2,02	2,00	1,96	1,94	1,91	1,90	1,88
	8,18	5,93	5,01	4,50	4,17	3,94	3,77	3,63	3,52	3,43	3,36	3,30	3,19	3,12	3,00	2,92	2,84	2,76	2,70	2,63	2,60	2,54	2,51	2,49
20	4,35	3,49	3,10	2,87	2,71	2,60	2,52	2,45	2,40	2,35	2,31	2,26	2,23	2,18	2,12	2,08	2,04	1,99	1,96	1,92	1,90	1,87	1,85	1,84
	8,10	5,85	4,94	4,43	4,10	3,87	3,71	3,56	3,45	3,37	3,30	3,23	3,13	3,05	2,94	2,86	2,77	2,69	2,63	2,56	2,53	2,47	2,44	2,42
21	4,32	3,47	3,07	2,84	2,68	2,57	2,49	2,42	2,37	2,32	2,28	2,25	2,20	2,15	2,09	2,05	2,00	1,96	1,93	1,89	1,87	1,84	1,82	1,81
	8,02	5,78	4,87	4,37	4,04	3,81	3,65	3,51	3,40	3,31	3,24	3,17	3,07	2,99	2,88	2,80	2,72	2,63	2,58	2,51	2,47	2,42	2,38	2,36
22	4,30	3,44	3,05	2,82	2,66	2,55	2,47	2,40	2,35	2,30	2,26	2,23	2,18	2,13	2,07	2,03	1,98	1,93	1,91	1,87	1,84	1,81	1,80	1,78
	7,94	5,72	4,82	4,31	3,99	3,76	3,59	3,45	3,35	3,26	3,18	3,12	3,02	2,94	2,83	2,75	2,67	2,58	2,53	2,46	2,42	2,37	2,33	2,31
23	4,28	3,42	3,03	2,80	2,64	2,53	2,45	2,38	2,32	2,28	2,24	2,20	2,14	2,10	2,04	2,00	1,96	1,91	1,88	1,84	1,82	1,79	1,77	1,76
	7,88	5,66	4,76	4,26	3,94	3,71	3,54	3,41	3,30	3,21	3,14	3,07	2,97	2,89	2,78	2,70	2,62	2,53	2,48	2,41	2,37	2,32	2,28	2,26

LAMPIRAN O

TABEL UJI R

DEGREES OF FREEDOM (DF)	5 PERCENT	1 PERCENT	DEGREES OF FREEDOM (DF)	5 PERCENT	1 PERCENT
1	.997	1.000	24	.388	.496
2	.950	.990	25	.381	.487
3	.878	.959	26	.374	.478
4	.811	.917	27	.367	.470
5	.754	.874	28	.361	.463
6	.707	.834	29	.355	.456
7	.666	.798	30	.349	.449
8	.632	.765	35	.325	.418
9	.602	.735	40	.304	.393
10	.576	.708	48	.288	.372
11	.553	.684	50	.273	.354
12	.532	.661	60	.250	.325
13	.514	.641	70	.232	.302
14	.497	.623	80	.217	.283
15	.482	.606	90	.205	.267
16	.468	.590	100	.195	.254
17	.456	.575	125	.174	.228
18	.444	.561	150	.159	.208
19	.433	.549	200	.138	.181
20	.423	.537	300	.113	.148
21	.413	.526	400	.098	.128
22	.404	.515	500	.088	.115
23	.396	.505	1000	.062	.081

Dikutip dari: Soedigdo & Soedigdo (1977)

LAMPIRAN P

TABEL UJI T

v	α				
	0.10	0.05	0.025	0.01	0.005
1	3.078	6.314	12.706	31.821	63.657
2	1.886	2.920	4.303	6.965	9.925
3	1.638	2.353	3.182	4.451	5.841
4	1.533	2.132	2.776	3.747	4.604
5	1.476	2.015	2.561	3.365	4.012
6	1.440	1.943	2.447	3.143	3.707
7	1.415	1.895	2.365	2.998	3.499
8	1.397	1.860	2.306	2.896	3.355
9	1.383	1.833	2.262	2.821	3.250
10	1.372	1.812	2.228	2.764	3.169
11	1.363	1.796	2.201	2.718	3.106
12	1.356	1.782	2.179	2.681	3.055
13	1.350	1.771	2.160	2.650	3.012
14	1.345	1.761	2.145	2.624	2.977
15	1.341	1.753	2.131	2.602	2.947
16	1.337	1.746	2.120	2.583	2.921
17	1.333	1.740	2.110	2.567	2.898
18	1.330	1.734	2.101	2.552	2.878
19	1.328	1.729	2.093	2.539	2.861
20	1.325	1.725	2.086	2.528	2.845
21	1.323	1.721	2.080	2.518	2.831
22	1.321	1.717	2.074	2.508	2.819
23	1.319	1.714	2.069	2.500	2.807
24	1.318	1.711	2.064	2.492	2.797
25	1.316	1.708	2.060	2.485	2.787
26	1.315	1.706	2.056	2.479	2.779
27	1.314	1.703	2.052	2.473	2.771
28	1.313	1.701	2.048	2.467	2.763
29	1.311	1.699	2.045	2.462	2.756
inf.	1.282	1.645	1.960	2.326	2.576

Sumber : Ronald E. Walpole (1995) : Pengantar Statistika.

LAMPIRAN Q

HASIL UJI STATISTIK KEKERASAN ODT DOMPERIDONE

Descriptives

Kekerasan

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Minimum	Maximum
					Lower Bound	Upper Bound		
I	3	2.8933	.17502	.10105	2.4586	3.3281	2.72	3.07
II	3	2.7867	.06506	.03756	2.6250	2.9483	2.72	2.85
III	3	3.2233	.13051	.07535	2.8991	3.5475	3.12	3.37
IV	3	2.8633	.31660	.18279	2.0769	3.6498	2.53	3.16
Total	12	2.9417	.24117	.06962	2.7884	3.0949	2.53	3.37

Test of Homogeneity of Variances

Kekerasan

Levene Statistic	df1	df2	Sig.
1.668	3	8	.250

ANOVA

Kekerasan

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	.335	3	.112	2.940	.099
Within Groups	.304	8	.038		
Total	.640	11			

Keterangan:

Ho ditolak jika F_{hitung} (2,940) < $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata kekerasan ODT domperidone dari keempat formula menunjukkan bahwa tidak ada perbedaan yang signifikan antar formula.

LAMPIRAN R

HASIL UJI STATISTIK KERAPUHAN ODT DOMPERIDONE

Descriptives

Kerapuhan

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Minimum	Maximum
					Lower Bound	Upper Bound		
I	3	.6467	.25423	.14678	.0151	1.2782	.49	.94
II	3	1.1233	.29195	.16856	.3981	1.8486	.94	1.46
III	3	.3200	.27731	.16010	-.3689	1.0089	.00	.49
IV	3	.9767	.02517	.01453	.9142	1.0392	.95	1.00
Total	12	.7667	.38263	.11046	.5236	1.0098	.00	1.46

Test of Homogeneity of Variances

Kerapuhan

Levene Statistic	df1	df2	Sig.
4.424	3	8	.041

ANOVA

Kerapuhan

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	1.156	3	.385	6.776	.014
Within Groups	.455	8	.057		
Total	1.610	11			

Keterangan:

Ho ditolak jika F_{hitung} (6,776) > $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata kerapuhan tablet dari keempat formula menunjukkan bahwa ada perbedaan yang signifikan antar formula.

Multiple Comparisons

Kerapuhan
LSD

(I) Formula	(J) Formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
I	II	-.47667*	.19468	.040	-.9256	-.0277
	III	.32667	.19468	.132	-.1223	.7756
	IV	-.33000	.19468	.129	-.7789	.1189
II	I	.47667*	.19468	.040	.0277	.9256
	III	.80333*	.19468	.003	.3544	1.2523
	IV	.14667	.19468	.473	-.3023	.5956
III	I	-.32667	.19468	.132	-.7756	.1223
	II	-.80333*	.19468	.003	-1.2523	-.3544
	IV	-.65667*	.19468	.010	-1.1056	-.2077
IV	I	.33000	.19468	.129	-.1189	.7789
	II	-.14667	.19468	.473	-.5956	.3023
	III	.65667*	.19468	.010	.2077	1.1056

*. The mean difference is significant at the 0.05 level.

Keterangan:

Hasil uji LSD dari keempat formula, diperoleh nilai sig. < α (0,05) sehingga Ho ditolak (*), berarti rata-rata kerapuhan tablet dari keempat formula menunjukkan bahwa ada perbedaan yang signifikan antar formula yaitu formula I menunjukkan perbedaan yang signifikan terhadap formula II; formula II menunjukkan perbedaan yang signifikan terhadap formula I dan formula III; formula III menunjukkan perbedaan yang signifikan terhadap formula II dan formula IV; dan formula IV menunjukkan perbedaan yang signifikan terhadap formula III.

LAMPIRAN S

HASIL UJI STATISTIK WAKTU HANCUR ODT DOMPERIDONE

Descriptives

Waktu_Hancur

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Minimum	Maximum
					Lower Bound	Upper Bound		
I	3	49.8667	8.92711	5.15407	27.6905	72.0428	40.20	57.80
II	3	36.4667	2.90057	1.67465	29.2612	43.6721	33.60	39.40
III	3	73.6667	7.36569	4.25258	55.3693	91.9640	65.80	80.40
IV	3	54.2000	10.44031	6.02771	28.2648	80.1352	42.20	61.20
Total	12	53.5500	15.47505	4.46726	43.7176	63.3824	33.60	80.40

Test of Homogeneity of Variances

Waktu_Hancur

Levene Statistic	df1	df2	Sig.
1.714	3	8	.241

ANOVA

Waktu_Hancur

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	2131.530	3	710.510	11.307	.003
Within Groups	502.720	8	62.840		
Total	2634.250	11			

Keterangan:

Ho ditolak jika F_{hitung} (11,307) > $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata waktu hancur tablet dari keempat formula menunjukkan bahwa ada perbedaan yang signifikan antar formula.

Multiple Comparisons

Waktu_Hancur
LSD

(I) Formula	(J) Formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
I	II	13.40000	6.47251	.072	-1.5256	28.3256
	III	-23.80000*	6.47251	.006	-38.7256	-8.8744
	IV	-4.33333	6.47251	.522	-19.2590	10.5923
II	I	-13.40000	6.47251	.072	-28.3256	1.5256
	III	-37.20000*	6.47251	.000	-52.1256	-22.2744
	IV	-17.73333*	6.47251	.025	-32.6590	-2.8077
III	I	23.80000*	6.47251	.006	8.8744	38.7256
	II	37.20000*	6.47251	.000	22.2744	52.1256
	IV	19.46667*	6.47251	.017	4.5410	34.3923
IV	I	4.33333	6.47251	.522	-10.5923	19.2590
	II	17.73333*	6.47251	.025	2.8077	32.6590
	III	-19.46667*	6.47251	.017	-34.3923	-4.5410

*. The mean difference is significant at the 0.05 level.

Keterangan:

Hasil uji LSD dari keempat formula, diperoleh nilai sig. < α (0,05) sehingga Ho ditolak (*), berarti rata-rata waktu hancur tablet dari keempat formula menunjukkan bahwa ada perbedaan yang signifikan antar formula yaitu formula I menunjukkan perbedaan yang signifikan terhadap formula III; formula II menunjukkan perbedaan yang signifikan terhadap formula III dan formula IV; formula III menunjukkan perbedaan yang signifikan terhadap ketiga formula yang lainnya; dan formula IV menunjukkan perbedaan yang signifikan terhadap formula II dan formula III.

LAMPIRAN T

HASIL UJI STATISTIK WAKTU PEMBASAHAN ODT DOMPERIDONE

Descriptives

Waktu_Pembasahan

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
I	3	49.3300	10.14889	5.85947	24.1188	74.5412	40.33	60.33
II	3	52.5567	2.00241	1.15609	47.5824	57.5309	50.50	54.50
III	3	68.8367	10.26320	5.92546	43.3415	94.3319	60.17	80.17
IV	3	69.0567	18.07981	10.43838	24.1439	113.9694	55.17	89.50
Total	12	59.9450	13.70632	3.95667	51.2364	68.6536	40.33	89.50

Test of Homogeneity of Variances

Waktu_Pembasahan

Levene Statistic	df1	df2	Sig.
3.286	3	8	.079

ANOVA

Waktu_Pembasahan

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	988.050	3	329.350	2.443	.139
Within Groups	1078.445	8	134.806		
Total	2066.495	11			

Keterangan:

Ho ditolak jika F_{hitung} (2,443) < $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata waktu pembasahan ODT domperidone dari keempat formula menunjukkan bahwa tidak ada perbedaan yang signifikan antar formula.

LAMPIRAN U

HASIL UJI STATISTIK RASIO ABSORPSI AIR ODT DOMPERIDONE

Descriptives

Rasio_Absorpsi_Air

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
I	3	55.7700	9.84276	5.68272	31.3192	80.2208	47.20	66.52
II	3	67.9533	10.12525	5.84581	42.8008	93.1058	58.46	78.61
III	3	66.5967	9.78770	5.65093	42.2827	90.9107	55.85	75.00
IV	3	78.5967	3.83010	2.21131	69.0822	88.1112	74.52	82.12
Total	12	67.2292	11.29807	3.26147	60.0507	74.4076	47.20	82.12

Test of Homogeneity of Variances

Rasio_Absorpsi_Air

Levene Statistic	df1	df2	Sig.
.852	3	8	.504

ANOVA

Rasio_Absorpsi_Air

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	784.371	3	261.457	3.375	.075
Within Groups	619.738	8	77.467		
Total	1404.109	11			

Keterangan:

Ho ditolak jika F_{hitung} (3,375) < $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata rasio absorpsi air ODT domperidone dari keempat formula menunjukkan bahwa tidak ada perbedaan yang signifikan antar formula.

LAMPIRAN V

HASIL UJI STATISTIK PERSEN OBAT TERLEPAS TABLET DOMPERIDONE PADA T=30 MENIT

Descriptives

Persen_obat_terlepas_t30

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
I	3	95.0267	1.79110	1.03409	90.5773	99.4760	93.39	96.94
II	3	94.4867	3.73149	2.15438	85.2171	103.7562	90.45	97.81
III	3	95.8733	2.16308	1.24886	90.4999	101.2467	94.30	98.34
IV	3	94.5133	2.69419	1.55549	87.8206	101.2061	91.70	97.07
P1	3	96.0667	1.34482	.77643	92.7260	99.4074	94.52	96.96
P2	3	93.2333	.51160	.29537	91.9625	94.5042	92.70	93.72
Total	18	94.8667	2.14925	.50658	93.7979	95.9355	90.45	98.34

Test of Homogeneity of Variances

Persen_obat_terlepas_t30

Levene Statistic	df1	df2	Sig.
1.692	5	12	.211

ANOVA

Persen_obat_terlepas_t30

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	16.248	5	3.250	.626	.683
Within Groups	62.280	12	5.190		
Total	78.528	17			

Keterangan:

Ho ditolak jika F_{hitung} (0,626) < $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata % obat terlepas pada t=30 menit ODT domperidone dari keempat formula, tablet generik domperidone, dan ODT domperidone dengan nama dagang menunjukkan bahwa tidak ada perbedaan yang signifikan antar formula.

LAMPIRAN W

HASIL UJI STATISTIK PERSEN EFISIENSI DISOLUSI TABLET DOMPERIDONE

Descriptives

Persen_ Efisiensi_Disolusi

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Min	Max
					Lower Bound	Upper Bound		
I	3	92.7733	3.30945	1.91071	84.5522	100.9945	89.30	95.89
II	3	94.1033	2.49268	1.43915	87.9112	100.2955	91.32	96.13
III	3	93.8700	.94979	.54836	91.5106	96.2294	92.98	94.87
IV	3	94.4333	.81347	.46966	92.4126	96.4541	93.52	95.08
P1	3	91.4467	2.11588	1.22160	86.1905	96.7028	90.04	93.88
P2	3	92.7233	.76827	.44356	90.8149	94.6318	91.87	93.36
Total	18	93.2250	1.97619	.46579	92.2423	94.2077	89.30	96.13

Test of Homogeneity of Variances

Persen_ Efisiensi_Disolusi

Levene Statistic	df1	df2	Sig.
1.692	5	12	.211

ANOVA

Persen_ Efisiensi_Disolusi

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	16.248	5	3.250	.626	.683
Within Groups	62.280	12	5.190		
Total	78.528	17			

Keterangan:

Ho ditolak jika F_{hitung} (0,626) < $F_{tabel\ 0,05\ (3,8)}$ (4,07), berarti rata-rata % efisiensi disolusi ODT domperidone dari keempat formula, tablet generik domperidone, dan ODT domperidone dengan nama dagang menunjukkan bahwa tidak ada perbedaan yang signifikan antar formula.

LAMPIRAN X

UJI F KURVA BAKU DENGAN HCl 0,1 N UNTUK UJI PENETAPAN KADAR ODT DOMPERIDONE

Rep.	Konsentrasi (ppm) (x)	Absorbansi (y)	x^2	y^2	xy
I	2,012	0,097	4,0481	0,0094	0,1952
	4,024	0,140	16,1926	0,0196	0,5634
	6,036	0,203	36,4333	0,0412	1,2253
	8,048	0,253	64,7703	0,0640	2,0361
	10,06	0,313	101,2036	0,0980	3,1488
	12,072	0,372	145,7332	0,1384	4,4908
∑	14,084	0,426	198,3591	0,1815	5,9998

Persamaan Regresi pada replikasi 1 → y = 0,0277x + 0,0347

r_{hitung}/r_{tabel}: 0,9993/0,754

Rep.	Konsentrasi (ppm) (x)	Absorbansi (y)	x^2	y^2	xy
II	2,012	0,090	4,0481	0,0081	0,1811
	4,024	0,145	16,1926	0,0210	0,5835
	6,036	0,195	36,4333	0,0380	1,1770
	8,048	0,260	64,7703	0,0676	2,0925
	10,06	0,319	101,2036	0,1018	3,2091
	12,072	0,371	145,7332	0,1376	4,4787
∑	14,084	0,426	198,3591	0,1815	5,9998

Persamaan Regresi pada replikasi 2 → y = 0,0283x + 0,0306

r_{hitung}/r_{tabel}: 0,9996/0,754

Rep.	Konsentrasi (ppm) (x)	Absorbansi (y)	x^2	y^2	xy
III	2,008	0,089	4,0321	0,0079	0,1787
	4,016	0,139	16,1283	0,0193	0,5582
	6,024	0,210	36,2886	0,0441	1,2650
	8,032	0,264	64,5130	0,0697	2,1204
	10,04	0,326	100,8016	0,1063	3,2730
	12,048	0,373	145,1543	0,1391	4,4939
∑	14,056	0,426	197,5711	0,1815	5,9879

Persamaan Regresi pada replikasi 3 → y = 0,0284x + 0,0306

r_{hitung}/r_{tabel}: 0,9988/0,754

	$\sum x^2$	$\sum xy$	$\sum y^2$	n	Residual SS	RDF
Persamaan regresi 1	566,7402	17,65932	0,552056	7	0,001801	5
Persamaan regresi 2	566,7402	17,77803	0,559052	7	0,001374	5
Persamaan regresi 3	564,489	17,87722	0,567919	7	0,001752	5
Pooled regression				21	0,004927	15
Common regression	1697,969	53,31458	1,679027		0,005001	15

F_{hitung} = 0,056636

$F_{tabel\ 0,05\ (4,15)}$ = 3,06

F_{hitung} = 0,056636 < $F_{tabel\ 0,05\ (4,15)}$ = 3,06; yang berarti tidak ada perbedaan bermakna antar replikasi pada pembuatan kurva baku untuk uji penetapan kadar ODT domperidone.

LAMPIRAN Y

HASIL UJI ANAVA KEKERASAN ODT DOMPERIDONE DENGAN *DESIGN EXPERT*

Use your mouse to right click on individual cells for definitions.
Response 1 Kekerasan
ANOVA for selected factorial model
Analysis of variance table [Partial sum of squares - Type III]

Source	Sum of Squares	Df	Mean Square	F Value	p-value Prop > F	
Model	0.34	3	0.11	2.94	0.0989	not significant
A-Ac-Di-Sol	0.16	*1*	0.16	4.29	0.0720	
B- Gelatin	0.12	*1*	0.12	3.26	0.1086	
AB	0.048	*1*	0.048	1.27	0.2932	
Pure Error	0.30	8	0.038			
Cor Total	0.64	11				

The Model F-value of 2.94 implies there is a 9.89% chance that a "Model F-Value" this large could occur due to noise.
Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case there are no significant model terms.
Values greater than 0.1000 indicate the model terms are not significant.
If there are many insignificant model terms (not counting those required to support hierarchy), model reduction may improve your model.

Std. Dev.	0.20	R-Squared	0.5244
Mean	2.94	Adj R-Squared	0.3461
C.V. %	6.63	Pred R-Squared	-0.0701
PRESS	0.68	Adeq Precision	3.878

A negative "Pred R-Squared" implies that the overall mean is a better predictor of your response than the current model.

"Adeq Precision" measures the signal to noise ratio. A ratio of 3.88 indicates an inadequate signal and we should not use this model to navigate the design space.

Factor	Coefficient Estimate	df	Standard Error	95% CI Low	95% CI High	VIF
Intercept	2.94	1	0.056	2.81	3.07	
A-Ac-Di-Sol	-0.12	1	0.056	-0.25	0.013	1.00
B-Gelatin	0.10	1	0.056	-0.028	0.23	1.00
AB	-0.063	1	0.056	-0.19	0.066	1.00

Final Equation in Terms of Coded Factors:

Kekerasan =
+2.94
-0.12 * A
+0.10 * B
-0.063 * A * B

Final Equation in Terms of Actual Factors:

Kekerasan =
+2.94167
-0.11667 * Ac-Di-Sol
+0.10167 * Gelatin
-0.063333 * Ac-Di-Sol * Gelatin

The Diagnostics Case Statistics Report has been moved to the Diagnostics Node.
In the Diagnostics Node, Select Case Statistics from the View Menu.

Proceed to Diagnostic Plots (the next icon in progression). Be sure to look at the:
1) Normal probability plot of the studentized residuals to check for normality of residuals.
2) Studentized residuals versus predicted values to check for constant error.
3) Externally Studentized Residuals to look for outliers, i.e., influential values.
4) Box-Cox plot for power transformations.

If all the model statistics and diagnostic plots are OK, finish up with the Model Graphs icon.

LAMPIRAN Z

HASIL UJI ANAVA KERAPUHAN ODT DOMPERIDONE DENGAN *DESIGN EXPERT*

Use your mouse to right click on individual cells for definitions.
Response 2 Kerapuhan
ANOVA for selected factorial model
Analysis of variance table [Partial sum of squares - Type III]

Source	Sum of Squares	Df	Mean Square	F Value	p-value Prop > F	
Model	1.16	3	0.39	6.78	0.0138	significant
A-Ac-Di-Sol	*0.96*	*1*	0.96	16.95	0.0034	
B- Gelatin	*0.17*	*1*	0.17	2.96	0.1239	
AB	*0.024*	*1*	0.024	0.43	0.5316	
Pure Error	0.45	8	0.057			
Cor Total	1.61	11				

The Model F-value of 6.78 implies the model is significant. There is only a 1.38% chance that a "Model F-Value" this large could occur due to noise.

Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case A are significant model terms.
Values greater than 0.1000 indicate the model terms are not significant.
If there are many insignificant model terms (not counting those required to support hierarchy),
model reduction may improve your model.

Std. Dev.	0.24	R-Squared	0.7176
Mean	0.77	Adj R-Squared	0.6117
C.V. %	31.10	Pred R-Squared	0.3646
PRESS	1.02	Adeq Precision	5.836

The "Pred R-Squared" of 0.3646 is not as close to the "Adj R-Squared" of 0.6117 as one might normally expect. This may indicate a large block effect or a possible problem with your model and/or data. Things to consider are model reduction, response transformation, outliers, etc.

"Adeq Precision" measures the signal to noise ratio. A ratio greater than 4 is desirable. Your ratio of 5.836 indicates an adequate signal. This model can be used to navigate the design space.

Factor	Coefficient Estimate	df	Standard Error	95% CI Low	95% CI High	VIF
Intercept	0.77	1	0.069	0.61	0.93	
A-Ac-Di-Sol	0.28	1	0.069	0.12	0.44	1.00
B-Gelatin	-0.12	1	0.069	-0.28	0.040	1.00
AB	0.045	1	0.069	-0.11	0.20	1.00

Final Equation in Terms of Coded Factors:

Kerapuhan =
+0.77
+0.28 * A
-0.12 * B
+0.045 * A * B

Final Equation in Terms of Actual Factors:

Kerapuhan =
+0.76667
+0.28333 * Ac-Di-Sol
-0.11833 * Gelatin
+0.045000 * Ac-Di-Sol * Gelatin

The Diagnostics Case Statistics Report has been moved to the Diagnostics Node.
In the Diagnostics Node, Select Case Statistics from the View Menu.

Proceed to Diagnostic Plots (the next icon in progression). Be sure to look at the:
1) Normal probability plot of the studentized residuals to check for normality of residuals.
2) Studentized residuals versus predicted values to check for constant error.
3) Externally Studentized Residuals to look for outliers, i.e., influential values.
4) Box-Cox plot for power transformations.

If all the model statistics and diagnostic plots are OK, finish up with the Model Graphs icon.

LAMPIRAN AA

HASIL UJI ANAVA WAKTU HANCUR ODT DOMPERIDONE

DENGAN *DESIGN EXPERT*

Use your mouse to right click on individual cells for definitions.
Response 3 Waktu Hancur
ANOVA for selected factorial model
Analysis of variance table [Partial sum of squares - Type III]

Source	Sum of Squares	Df	Mean Square	F Value	p-value Prop > F	
Model	2131.53	3	710.51	11.31	0.0030	significant
A-Ac-Di-Sol	810.16	*1*	810.16	12.89	0.0071	
B- Gelatin	1293.76	*1*	1293.76	20.59	0.0019	
AB	27.60	*1*	27.60	0.44	0.5261	
Pure Error	502.72	8	62.84			
Cor Total	2634.25	11				

The Model F-value of 11.31 implies the model is significant. There is only a 0.30% chance that a "Model F-Value" this large could occur due to noise.

Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case A, B are significant model terms.
Values greater than 0.1000 indicate the model terms are not significant.
If there are many insignificant model terms (not counting those required to support hierarchy),
model reduction may improve your model.

Std. Dev.	7.93	R-Squared	0.8092
Mean	53.55	Adj R-Squared	0.7376
C.V. %	14.80	Pred R-Squared	0.5706
PRESS	1131.12	Adeq Precision	8.128

The "Pred R-Squared" of 0.5706 is in reasonable agreement with the "Adj R-Squared" of 0.7376.

"Adeq Precision" measures the signal to noise ratio. A ratio greater than 4 is desirable. Your ratio of 8.128 indicates an adequate signal. This model can be used to navigate the design space.

Factor	Coefficient Estimate	df	Standard Error	95% CI Low	95% CI High	VIF
Intercept	53.55	1	2.29	48.27	58.83	
A-Ac-Di-Sol	-8.22	1	2.29	-13.49	-2.94	1.00
B-Gelatin	10.38	1	2.29	5.11	15.66	1.00
AB	-1.52	1	2.29	-6.79	3.76	1.00

Final Equation in Terms of Coded Factors:

Waktu Hancur =
+53.55
-8.22 * A
+10.38 * B
-1.52 * A * B

Final Equation in Terms of Actual Factors:

Waktu Hancur =
+53.55000
-8.21667 * Ac-Di-Sol
+10.38333 * Gelatin
-1.51667 * Ac-Di-Sol * Gelatin

The Diagnostics Case Statistics Report has been moved to the Diagnostics Node.
In the Diagnostics Node, Select Case Statistics from the View Menu.

Proceed to Diagnostic Plots (the next icon in progression). Be sure to look at the:
1) Normal probability plot of the studentized residuals to check for normality of residuals.
2) Studentized residuals versus predicted values to check for constant error.
3) Externally Studentized Residuals to look for outliers, i.e., influential values.
4) Box-Cox plot for power transformations.

If all the model statistics and diagnostic plots are OK, finish up with the Model Graphs icon.

LAMPIRAN AB

HASIL UJI ANAVA WAKTU PEMBASAHAN

ODT DOMPERIDONE DENGAN *DESIGN EXPERT*

Use your mouse to right click on individual cells for definitions.
Response 4 Waktu Pembasahan
ANOVA for selected factorial model
Analysis of variance table [Partial sum of squares - Type III]

Source	Sum of Squares	Df	Mean Square	F Value	p-value Prop > F	
Model	989.53	3	329.84	2.45	0.1385	not significant
A-Ac-Di-Sol	8.74	*1*	8.74	0.065	0.8054	
B- Gelatin	974.16	*1*	974.16	7.23	0.0276	
AB	6.63	*1*	6.63	0.049	0.8300	
Pure Error	1078.06	8	134.76			
Cor Total	2067.59	11				

The "Model F-value" of 2.45 implies the model is not significant relative to the noise. There is a 13.85 % chance that a "Model F-value" this large could occur due to noise.

Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case B are significant model terms.
Values greater than 0.1000 indicate the model terms are not significant.
If there are many insignificant model terms (not counting those required to support hierarchy), model reduction may improve your model.

Std. Dev.	11.61	R-Squared	0.4786
Mean	59.94	Adj R-Squared	0.2831
C.V. %	19.37	Pred R-Squared	-0.1732
PRESS	2425.64	Adeq Precision	2.943

A negative "Pred R-Squared" implies that the overall mean is a better predictor of your response than the current model.

"Adeq Precision" measures the signal to noise ratio. A ratio of 2.94 indicates an inadequate signal and we should not use this model to navigate

the design space.

Factor	Coefficient Estimate	df	Standard Error	95% CI Low	95% CI High	VIF
Intercept	59.94	1	3.35	52.21	67.66	
A-Ac-Di-Sol	0.85	1	3.35	-6.87	8.58	1.00
B-Gelatin	9.01	1	3.35	1.28	16.74	1.00
AB	-0.74	1	3.35	-8.47	6.98	1.00

Final Equation in Terms of Coded Factors:

Waktu Pembasahan =
+59.94
+0.85 * A
+9.01 * B
-0.74 * A * B

Final Equation in Terms of Actual Factors:

Waktu Pembasahan =
+59.93667
+0.85333 * Ac-Di-Sol
+9.01000 * Gelatin
-0.74333 * Ac-Di-Sol * Gelatin

The Diagnostics Case Statistics Report has been moved to the Diagnostics Node.
In the Diagnostics Node, Select Case Statistics from the View Menu.

Proceed to Diagnostic Plots (the next icon in progression). Be sure to look at the:
1) Normal probability plot of the studentized residuals to check for normality of residuals.
2) Studentized residuals versus predicted values to check for constant error.
3) Externally Studentized Residuals to look for outliers, i.e., influential values.
4) Box-Cox plot for power transformations.

If all the model statistics and diagnostic plots are OK, finish up with the Model Graphs icon.

LAMPIRAN AC

HASIL UJI ANAVA RASIO ABSORPSI AIR ODT DOMPERIDONE

DENGAN *DESIGN EXPERT*

Use your mouse to right click on individual cells for definitions.
Response 5 Rasio Absorpsi Air
ANOVA for selected factorial model
Analysis of variance table [Partial sum of squares - Type III]

Source	Sum of Squares	Df	Mean Square	F Value	p-value Prop > F	
Model	784.37	3	261.46	3.38	0.0750	not significant
A-Ac-Di-Sol	438.63	*1*	438.63	5.66	0.0446	
B- Gelatin	345.72	*1*	345.72	4.46	0.0676	
AB	0.025	*1*	0.025	3.254E-004	0.9860	
Pure Error	619.74	8	77.47			
Cor Total	1404.11	11				

The Model F-value of 3.38 implies there is a 7.50% chance that a "Model F-Value" this large could occur due to noise.
Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case A are significant model terms.
Values greater than 0.1000 indicate the model terms are not significant.
If there are many insignificant model terms (not counting those required to support hierarchy), model reduction may improve your model.

Std. Dev.	8.80	R-Squared	0.5586
Mean	67.23	Adj R-Squared	0.3931
C.V. %	13.09	Pred R-Squared	0.0069
PRESS	1394.41	Adeq Precision	4.492

The "Pred R-Squared" of 0.0069 is not as close to the "Adj R-Squared" of 0.3931 as one might normally expect. This may indicate a large block effect or a possible problem with your model and/or data. Things to consider are model reduction, response transformation, outliers, etc.
"Adeq Precision" measures the signal to noise ratio. A ratio greater than 4 is desirable. Your ratio of 4.492 indicates an adequate signal. This model can be used to navigate the design space.

Factor	Coefficient Estimate	df	Standard Error	95% CI Low	95% CI High	VIF
Intercept	67.23	1	2.54	61.37	73.09	
A-Ac-Di-Sol	6.05	1	2.54	0.19	11.90	1.00
B-Gelatin	5.37	1	2.54	-0.49	11.23	1.00
AB	-0.046	1	2.54	-5.90	5.81	1.00

Final Equation in Terms of Coded Factors:

Rasio Absorbsi Air =
+67.23
+6.05 * A
+5.37 * B
-0.046 * A * B

Final Equation in Terms of Actual Factors:

Rasio Absorbsi Air =
+67.22917
+6.04583 * Ac-Di-Sol
+5.36750 * Gelatin
-0.045833 * Ac-Di-Sol * Gelatin

The Diagnostics Case Statistics Report has been moved to the Diagnostics Node. In the Diagnostics Node, Select Case Statistics from the View Menu.

Proceed to Diagnostic Plots (the next icon in progression). Be sure to look at the:
1) Normal probability plot of the studentized residuals to check for normality of residuals.
2) Studentized residuals versus predicted values to check for constant error.
3) Externally Studentized Residuals to look for outliers, i.e., influential values.
4) Box-Cox plot for power transformations.

If all the model statistics and diagnostic plots are OK, finish up with the Model Graphs icon.

LAMPIRAN AD

HASIL UJI ANAVA %ED ODT DOMPERIDONE DENGAN *DESIGN EXPERT*

Use your mouse to right click on individual cells for definitions.
Response 6 %Efisiensi Disolusi
ANOVA for selected factorial model
Analysis of variance table [Partial sum of squares - Type III]

Source	Sum of Squares	Df	Mean Square	F Value	p-value Prop > F	
Model	4.66	3	1.55	0.33	0.8031	not significant
A-Ac-Di-Sol	2.69	1	2.69	0.57	0.4703	
B-Gelatin	1.53	1	1.53	0.33	0.5837	
AB	0.44	1	0.44	0.094	0.7668	
Pure Error	37.46	8	4.68			
Cor Total	42.12	11				

The "Model F-value" of 0.33 implies the model is not significant relative to the noise. There is a 80.31 % chance that a "Model F-value" this large could occur due to noise.

Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case there are no significant model terms.
Values greater than 0.1000 indicate the model terms are not significant.
If there are many insignificant model terms (not counting those required to support hierarchy), model reduction may improve your model.

Std. Dev.	2.16	R-Squared	0.1106
Mean	93.80	Adj R-Squared	-0.2230
C.V. %	2.31	Pred R-Squared	-1.0013
PRESS	84.28	Adeq Precision	1.329

A negative "Pred R-Squared" implies that the overall mean is a better predictor of your response than the current model.
"Adeq Precision" measures the signal to noise ratio. A ratio of 1.33 indicates an inadequate signal and we should not use this model to navigate the design space.

Factor	Coefficient Estimate	df	Standard Error	95% CI Low	95% CI High	VIF
Intercept	93.80	1	0.62	92.35	95.24	
A-Ac-Di-Sol	0.47	1	0.62	-0.97	1.91	1.00
B-Gelatin	0.36	1	0.62	-1.08	1.80	1.00
AB	-0.19	1	0.62	-1.63	1.25	1.00

Final Equation in Terms of Coded Factors:

%ED =
+93.80
+0.47 * A
+0.36 * B
-0.19 * A * B

Final Equation in Terms of Actual Factors:

%ED =
+93.79500
+0.47333 * Ac-Di-Sol
+0.35667 * Gelatin
-0.19167 * Ac-Di-Sol * Gelatin

The Diagnostics Case Statistics Report has been moved to the Diagnostics Node.
In the Diagnostics Node, Select Case Statistics from the View Menu.

Proceed to Diagnostic Plots (the next icon in progression). Be sure to look at the:
1) Normal probability plot of the studentized residuals to check for normality of residuals.
2) Studentized residuals versus predicted values to check for constant error.
3) Externally Studentized Residuals to look for outliers, i.e., influential values.
4) Box-Cox plot for power transformations.

If all the model statistics and diagnostic plots are OK, finish up with the Model Graphs icon.

LAMPIRAN AE

HASIL UJI STATISTIK HASIL PERCOBAAN DAN HASIL TEORITIS PADA UJI KEKERASAN ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Kekerasan_Percobaan	2.941650	4	.1930567	.0965284
	Kekerasan_Teoritis	2.940000	4	.1944874	.0972437

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Kekerasan_Percobaan & Kekerasan_Teoritis	4	1.000	.000

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Dev.	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	Kekerasan_Percobaan - Kekerasan_Teoritis	.00165	.00433	.00216	-.005241	.00854	.762	3	.502

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (0,762) < $T_{0,025\ (3)}$ (3,182), berarti hasil percobaan dan hasil teoritis pada uji kekerasan tidak berbeda bermakna.

LAMPIRAN AF

HASIL UJI STATISTIK HASIL PERCOBAAN DAN HASIL TEORITIS PADA UJI KERAPUHAN ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Kerapuhan_Percobaan	.764650	4	.3575700	.1787850
	Kerapuhan_Teoritis	.770000	4	.3555747	.1777873

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Kerapuhan_Percobaan & Kerapuhan_Teoritis	4	1.000	.000

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Dev.	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	Kerapuhan_Percobaan - Kerapuhan_Teoritis	-.00535	.00404	.00202	-.011781	.00108	-2.64	3	.077

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (-2,64) < $T_{0,025\ (3)}$ (3,182), berarti hasil percobaan dan hasil teoritis pada uji kerapuhan tidak berbeda bermakna.

LAMPIRAN AG

HASIL UJI STATISTIK HASIL PERCOBAAN DAN HASIL TEORITIS PADA UJI WAKTU HANCUR ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Waktu_Hancur_Percobaan	53.550025	4	15.3894981	7.6947491
	Waktu_Hancur_Teoritis	53.550000	4	15.7973711	7.8986855

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Waktu_Hancur_Percobaan & Waktu_Hancur_Teoritis	4	1.000	.000

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Dev.	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	Waktu_Hancur_Percobaan - Waktu_Hancur_Teoritis	.000025	.5158	.2579	-.820735	.820785	.000	3	1.000

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (0,000) < $T_{0,025\ (3)}$ (3,182), berarti hasil percobaan dan hasil teoritis pada uji waktu hancur tidak berbeda bermakna.

LAMPIRAN AH

HASIL UJI STATISTIK HASIL PERCOBAAN DAN HASIL TEORITIS PADA UJI WAKTU PEMBASAHAN ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Waktu_Pembasahan_Percobaan	59.944450	4	10.4756275	5.2378138
	Waktu_Pembasahan_Teoritis	59.940000	4	10.4849225	5.2424613

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Waktu_Pembasahan_Percobaan & Waktu_Pembasahan_Teoritis	4	1.000	.000

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Dev.	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	Waktu_Pembasahan_Percobaan - Waktu_Pembasahan_Teoritis	.00445	.02079	.01040	-.028639	.03754	.428	3	.698

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (0,428) < $T_{0,025\ (3)}$ (3,182), berarti hasil percobaan dan hasil teoritis pada uji waktu pembasahan tidak berbeda bermakna.

LAMPIRAN AI

HASIL UJI STATISTIK HASIL PERCOBAAN DAN HASIL TEORITIS PADA UJI RASIO ABSORPSI AIR ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Rasio_Absorpsi_Air_Percobaan	67.230175	4	9.3360600	4.6680300
	Rasio_Absorpsi_Air_Teoritis	67.230000	4	9.3324249	4.6662125

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Rasio_Absorpsi_Air_Percobaan & Rasio_Absorpsi_Air_Teoritis	4	1.000	.000

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Dev.	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	Rasio_Absorpsi_Air_Percobaan - Rasio_Absorpsi_Air_Teoritis	.00017	.00713	.00356	-.011167	.01152	.049	3	.964

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (0,049) < $T_{0,025\ (3)}$ (3,182), berarti hasil percobaan dan hasil teoritis pada uji rasio absorpsi air tidak berbeda bermakna.

LAMPIRAN AJ

HASIL UJI STATISTIK HASIL PERCOBAAN DAN HASIL TEORITIS %ED ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	ED_Percobaan	93.794300	4	.7191960	.3595980
	ED_Teoritis	93.800000	4	.7179601	.3589800

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	ED_Percobaan & ED_Teoritis	4	1.000	.000

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Dev.	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	ED_Percobaan - ED_Teoritis	0056996	.00614	.003071	-.01547	.00407	-1.856	3	.16

Hipotesa Pengujian :

Ho diterima jika T_{hitung} (-1,856) < $T_{0,025\ (3)}$ (3,182), berarti hasil percobaan dan hasil teoritis pada uji rasio absorpsi air tidak berbeda bermakna.

LAMPIRAN AK

HASIL UJI STATISTIK STABILITAS WAKTU HANCUR ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Waktu_Hancur_Awal	53.5525	4	15.38945	7.69473
	Waktu_Hancur_Stabilitas	44.7833	4	13.92992	6.96496

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Waktu_Hancur_Awal & Waktu_Hancur_Stabilitas	4	.993	.007

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Dev.	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	Waktu_Hancur_Awal - Waktu_Hancur_Stabilitas	8.7692	2.2799	1.1399	5.1414	12.3969	7.693	3	.005

Hipotesa Pengujian :

Ho ditolak jika T_{hitung} (7,693) > $T_{0,025\ (3)}$ (3,182), berarti hasil stabilitas waktu hancur sebelum dan setelah penyimpanan selama 1 bulan berbeda bermakna.

LAMPIRAN AL

HASIL UJI STATISTIK STABILITAS WAKTU PEMBASAHAN ODT DOMPERIDONE

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Waktu_Pembasahan_Awal	59.9450	4	10.47605	5.23803
	Waktu_Pembasahan_Stabilitas	59.4172	4	10.40410	5.20205

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Waktu_Pembasahan_Awal & Waktu_Pembasahan_Stabilitas	4	1.000	.000

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Dev.	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	Waktu_Pembasahan_Awal - Waktu_Pembasahan_Stabilitas	.52778	.28061	.14030	.08127	.97429	3.762	3	.033

Hipotesa Pengujian :

Ho ditolak jika T_{hitung} (3,762) < $T_{0,025\ (3)}$ (3,182), berarti hasil stabilitas waktu pembasahan sebelum dan setelah penyimpanan selama 1 bulan berbeda bermakna.